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Definitions and abbreviations 
ADT: Androgen deprivation therapy 
ATC: Anatomical Therapeutic Classification 
AUA: American Urological Association 
CF: Chronic fatigue 
CI: Confidence interval 
CRN: Cancer Registry of Norway 
CT: Computed tomography 
CTCAE: Common Terminology Criteria for Adverse Events 
CurCands: Candidates for curative treatment 
EAU: European Association of Urology 
ECOG: Eastern Cooperative Oncology Group  
EORTC: European Organization for Research and Treatment of Cancer 
FACT: Functional Assessment of Cancer Therapy scale  
Gn-RH-agonists: Gonadotropin-releasing hormone agonists 
Gy: Gray 
HTcont: Definitive radiotherapy with ongoing neoadjuvant/adjuvant androgen deprivation 
therapy (hormone therapy continued) 
HTdis: Definitive radiotherapy with discontinued neoadjuvant/adjuvant androgen deprivation 
therapy (hormone therapy discontinued) 
HRQoL: Health Related Quality of Life 
IARC: The International Agency of Research and Treatment of Cancer 
IPSS: The International Prostate Symptom Score 
Late/long-term adverse effects: Adverse effects persisting or occurring one year or more after 
start of local treatment 
Localized prostate cancer: in the current thesis the term refers to both localized and locally 
advanced prostate cancer (T1-3, N0-X, M0) 
LHRH-analogs: Luteinizing hormone releasing hormone-analogs 
MRI: Magnetic Resonance Imaging 
NCCN: National Comprehensive Cancer Network 
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(neo)adjuvant androgen deprivation therapy: expression used to describe hormone treatment 
received before and/or after definitive radiotherapy. (Neoadjuvant and/or adjuvant hormone 
therapy)  
NoPCR: Norwegian Prostate Cancer Registry 
NorPD: The Norwegian Prescription Database 
NPPC: National Program for Prostate Cancer  
PCa: Prostate cancer 
PSA: Prostate specific antigen 
RAD: Definitive radiotherapy as monotherapy 
RADHT: CurCands with definitive radiotherapy with neoadjuvant and or adjuvant hormone 
therapy 
RADNoHT: CurCands with definitive radiotherapy as monotherapy 
RP: Radical prostatectomy 
RTOG: Radiation Therapy Oncology Group 
SF-12: The Short-Form Health Survey-12 
SF-36: The Short-Form Health Survey-36 
SPCG-4: Scandinavian Prostate Cancer Group, study number 4 
TNM: Tumor, Node, Metastasis 
TUR-P: Trans-urethral resection of the prostate 
Typical adverse effects: urinary, sexual and bowel adverse effects 
QoL: Quality of Life 
WHO: World Health Organization 
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Chapter 1: Introduction 
1.1 Prostate cancer epidemiology 
Epidemiology of prostate cancer (PCa) the last three decades requires an understanding of the 
impact of prostate-specific antigen (PSA) testing. Since the late 1980ies the PSA test has 
enabled the detection of PCa and is most frequently used in developed countries [1]. The 
widespread use of the PSA test has contributed to a dramatic rise in PCa incidence. The 
period after its introduction is in clinical medicine often referred to as the PSA-era (in Norway 
starting early in the 1990ies) [2]. With the help of PSA testing latent cancers are increasingly 
detected  affecting the interpretation of PCa incidence and survival data [3]. As early cases are 
more often diagnosed, survival will increase, even in the absence of benefits from therapy [4]. 
However, the availability of PSA testing of asymptomatic men will detect a large proportion 
of PCa which would never been clinically diagnosed (over-diagnosis). Despite available PSA 
testing, 12% of PCa patients in the United Kingdom are still diagnosed with metastases [5]. In 
Norway, which is also without a national PSA screening program, 13% of the patients had 
metastases at diagnosis in 2005 [6]. In the PSA-era 30-45% of patients, initially clinically 
diagnosed with PCa confined within the prostate, had extracapsular growth when evaluating 
the histopathology of a prostatectomy specimen [7, 8]. 
 In 2002 PCa was the fifth most common cancer in the world with 679000 new cases 
[9]. PCa is mainly a disease of older men and the incidence increases with age [10]. In 2005 
in Norway, barely 1% of newly diagnosed men were younger than 50 years at diagnosis, 11% 
were between 50 and 59 years and 88% were 60 years and older [11]. Based on rates from 
2004-2008 the lifetime risk of PCa is estimated to be 16.48% (1 in 6 men) for men born today 
[12] 
 The worldwide incidence of PCa varies across countries and shows distinct ethnical 
differences [1]. PCa represented 15.3% of new cancer cases in men in developed countries 
and 4.3% in developing countries in the year 2000, but the incidence has increased for several 
years in both groups. Some of the highest incidences of PCa are observed in the USA and in 
the Scandinavian countries, and one of the lowest incidences are observed in China [13]. The 
varying incidence of PCa is dependent upon etiological factors affecting the true prevalence 
(detected and undetected) of the disease, the intensity of diagnostic procedures including PSA 
testing and on the registration routines.  
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 The International Agency of Research and Treatment of Cancer (IARC) estimated 
that worldwide 221000 men died from PCa in 2002 [9]. The estimated age-specific PCa 
mortality rates (deaths per 100 000 person years) increase with advancing age; 0.1 (15-44 
years), 1.9 (45-54 years), 11.8 (55-64 years) and 100.4 (65 years and more) [14]. Mortality 
rates also vary between populations and are low in Asian populations and in North Africa. 
The highest mortality rates are found in the Caribbean, Southern and Central Africa, Northern 
and Western Europe, Australia , and North and South America [9]. PCa mortality has been 
quite stable even in the presence of large increases in incidence, but has started to decrease in 
countries which started early with an extensive use of the PSA test and increased use of 
curative therapy [9, 15]. The relation between reduced mortality and increased use of curative 
therapy is however not definitely established. 
 
1.2 Prostate cancer in Norway 
PCa is a major cause of morbidity and mortality of the Norwegian male population. Data from 
the Cancer Registry of Norway (CRN) show that over 3800 new cases were diagnosed in 
2004 which is the cohort this thesis concerns. The average new number of cases per year had 
risen to 4145 for the five-year period 2005-2009 [16]. No national PSA screening program 
exists in Norway, but the test is widely used as part of health control in men without any 
symptoms (opportunistic screening). The Norwegian PCa mortality rates are among the 
highest in the world and only a slight decline can be seen the recent years (Figure 1) [16].  
1.3 Etiological factors 
The etiological factors and causal mechanisms of PCa are not well understood, but consist of 
both endogenous and exogenous factors and the interaction between them [17]. Most of the 
prostate consists of glandular cells, and histologically, PCa is usually an adenocarcinoma. The 
development of PCa requires circulating androgens and the function of a cytoplasmatic 
androgen receptor. Testosterone is taken up from the blood and converted to 
dihydrotestosterone through the enzymatic process driven by the enzyme 5-alpha reductase 
[18]. Dihydrotestosterone binds to the androgen receptor which is activated and the molecule 
translocates to the nucleus [19]. The dihydrotestosterone-androgen receptor complex binds to 
DNA within regulatory regions of the target genes, a process which is necessary for cell 
proliferation and tissue maintenance in both PCa and normal prostate tissue.  
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Heredity is estimated to account for around 5-10% of all PCa cases and 10-20% of PCa 
diagnosed before 60 years of age [20, 21]. Men with two or three first-degree relatives 
previously diagnosed with PCa have an 11-fold increased risk of developing the disease in 
their lifetime [22]. However associations found between relevant genes and risk of PCa are 
modest and sometimes inconsistent [17].  
 Since PCa probably develops after androgen influence of long duration, an 
unavoidable risk factor for PCa is age. An important notice is that autopsy studies have also 
found latent PCa in younger men (21-30 years) and that the prevalence of latent cancers 
across countries varies much less than incidence figures [23-25]. Risk factors may therefore 
also include factors which can stimulate the development of latent PCa into symptomatic 
disease. 
 
 

Figure 1: Trends in PCa incidence and mortality rates and 5-year relative survival proportions. 
From Cancer in Norway 2009 [16].             
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 Specific exogenous factors which increase the risk of PCa have not been identified. 
However, there are many indications that dietary and lifestyle factors may influence on the 
risk of PCa. Migration studies show that if Japanese men move to America their risk of 
clinical PCa will approach that of American men, which is generally much higher than in 
Japanese men [26, 27]. This indicates that environmental or lifestyle factors are involved in 
the development of clinical PCa. Dietary elements which are suggested to increase risk of PCa 
are for example high consumption of saturated fat, heterocyclic amines, milk and dairy 
products [28]. Several potential protective dietary factors have been under study such as 
tomatoes/lycopene, vitamin E, selenium, lignans and isoflavones among others [29]. As a 
result, consumption of cooked tomatoes [30] and omega-3 fatty acids [31] shows a small, but 
significant association with reduced risk of PCa. 
 
1.4 The natural history of prostate cancer   
The natural history of PCa is extremely varying, which complicates the debate concerning 
both screening and treatment. Some PCa tumors are aggressive and can develop into lethal 
metastatic disease within short time. However, most PCa remain confined to the prostate for a 
long time and may never represent a problem during a man’s lifetime [32]. Exact criteria for 
determining if a PCa tumor requires treatment are not identified and expected prognosis of 
untreated PCa is today determined from Gleason Score [33], level of PSA [34] and extent of 
the disease related to the primary tumor, and regional and distant metastases (TNM 
classification system for prostate cancer [35]). On the basis of prognostic studies in large 
cohorts these factors separate non-metastatic patients into risk groups which among other 
aspects determine further interventions [36].  
 PCa usually develops in the peripheral zone of the prostate gland. As it grows it 
extends through the prostatic capsule and may gradually infiltrate the seminal vesicles. 
Sometimes the tumor advances locally and grows into the urinary bladder or the rectum. The 
PCa tumor cells can acquire the abilities to migrate from the primary tumor into the blood 
stream and/or through the lymphatic system. This dissemination of tumor cells is a step in the 
process of developing distant and/or regional lymphatic metastases [37]. Typically, PCa 
metastasizes to the skeleton. However, the malignancy can spread to other organs such as 
lung and liver [38]. Patients with distant metastases cannot be cured and metastases are the 
most important cause of substantial morbidity and mortality in these patients [37]. In some 
patients, the dissemination of tumor cells and the development of distant metastases take 
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place early in the tumor development [39]. However, metastases from PCa can also develop 
several years after curative treatment, probably because of early dissemination of tumor cells 
which remain dormant for long periods [7, 40]. Search for new diagnostic and prognostic 
tools which better discriminate between “significant” and “insignificant” PCa is continuing 
and when this project was initiated the prostate cancer antigen 3 (PCA3) test was showing 
promising results [41].  
 
1.5 Staging 
In the present thesis the latest TNM (Tumor, Node, Metastasis) classification available at the 
time the patients under study were diagnosed was the 6th edition from 2002 (Table 1) [35].  
 
T-staging: The local extent of the tumor is evaluated using digital rectal examination 
of the patient as the standard procedure. Transrectal ultrasound visualizes the suspicious 
lesion and assists biopsy performance. Stage T1c denotes a non-palpable tumor detected on 
the basis of elevated PSA.  
N-staging: Definite statement as to pelvic lymph node status requires 
lymphadenectomy with histopathological examination of the resected tissue. Stage NX is used 
for patients without such diagnostic procedure. Evaluation of lymph node involvement is 
recommended only in those patients in whom a positive finding will influence on the decision 
of curative treatment. According to the European Association of Urology (EAU) guidelines 
from 2003 [38], lymph nodes on such patients should be examined unless patients have a low 
risk (<10%) of nodal metastases (T2a or less, PSA < 20 ng/ml and Gleason score 6 or less).  
M-staging: Distant metastases at diagnosis are most often found in the axial skeleton 
(85% of the cases) [42] and are assessed by bone scan. Metastases in soft tissue can be 
detected by computed tomography (CT) or magnetic resonance imaging (MRI). PSA 
exceeding 100ng/mL has proven to be highly associated with metastases [43]. According to 
the EAU guidelines from 2003, diagnostics to search for distant metastases is not required in 
asymptomatic patients with well-, or moderately differentiated tumors if the serum PSA level 
is less than 20 ng/mL. 
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Table 1: The 2002 TNM (Tumor Node Metastasis) classification system for prostate 
cancer [35] 
Evaluation of the primary tumor (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
T1: Clinically inapparent tumor not palpable or visible by imaging 
   T1a Tumor incidental histological finding in 5% or less of tissue resected 
   T1b Tumor incidental histological finding in  more than 5% of tissue resected 
   T1c Tumor identified by needle biopsy (e.g. because of elevated PSA level) 
T2: Tumor confined within the prostate1 
   T2a Tumor involves one half of one lobe or less 
   T2b Tumor involves more than half of one lobe, but not both lobes 
   T2c Tumor involves both lobes 
T3: Tumor extends through the prostatic capsule2 
   T3a Extracapsular extension (unilateral or bilateral) 
   T3b Tumor invades seminal vesicle(s) 
T4: Tumor is fixed to or invades adjacent structures other than seminal vesicles; bladder neck, external sphincter, 
rectum, levator muscles and/or pelvic wall 
Evaluation of the regional lymph nodes (N)3
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Regional lymph node metastasis 
Evaluation of distant metastasis (M)4
MX: Distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
   M1a Non-regional lymph nodes  
   M1b Bone(s) 
   M1c Other site(s) 
1 Tumor found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c. 
2 Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is not classified as T3, but as 
T2.
3 Metastasis no larger than 0.2 cm can be designated pN1mi. 
4 When more than one site of metastasis is present, the most advanced category should be used. 
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1.6 Prostate specific antigen 
PSA is a glycoprotein produced, almost exclusively, by the epithelial cells in the prostate. The 
serine protease is secreted from the prostate glands and into the seminal fluid. PSA is 
responsible for liquefaction of the semen when a man ejaculates. An elevated PSA is an 
indication of prostate disease, but is not PCa specific [44]. There is no generally accepted cut-
off level for serum PSA in diagnostics of non-palpable PCa, however <4 ng/mL is commonly 
used as a threshold in studies [38]. 
  
1.7 Histopathological grading 
Tissue from adenocarcinoma of the prostate is graded microscopically using the Gleason 
grading system [45] which describes how much the microscopic picture resembles normal 
prostatic tissue based on the growth pattern. The grading system ranges from 1 (good 
resemblance) to 5 (poor resemblance), thus making the tumor more aggressive with increasing 
grade. The Gleason score is given as the Gleason grade of the most common tumor pattern 
added with the Gleason grade of the second most common tumor pattern. This also implies 
that Gleason score 3+4=7 has a better prognosis than Gleason score 4+3=7 [46]. The most 
common tumor pattern must constitute of more than 50% of the tumor tissue seen and the 
second most common tumor pattern must constitute of less than 50%, but at least 5% of the 
tumor tissue seen. In 2005 a Gleason consensus conference recommended that the presence of 
Gleason grade 5 should always be scored (even if less than 5% of the tissue seen), because of 
a potentially poorer prognosis [47].  
 
1.8 Tumor risk groups 
Non-metastatic PCa is usually classified into prognostic categories before the optimal 
treatment strategy is considered. In this thesis we classified non-metastatic patients by the 
D’Amico risk group classification [2, 48] which takes into account the T-category, Gleason 
grade and the PSA level of the patient categorizing them into three prognostic groups: 
 
Low-risk: T1-T2a, PSA 10 ng/mL, Gleason score 6.  
Intermediate-risk: Not comprised by the low- or high-risk group definitions  
High-risk: T2c or PSA >20 or Gleason score 8.  
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Though not included in the original risk-categories of D’Amico et al [48] all T3 tumors are 
commonly classified to the high-risk group [49]. Compared to low-risk the relative risk of 
PCa specific mortality for intermediate- and high-risk PCa is approximately 5 and 14, 
respectively, for both radical prostatectomy (RP) and definitive radiotherapy [36]. The latter 
study with a median follow-up time of 4.1 years (range 0.5-14.3 years) for RP and 4.4 years 
(range 0.8-14.3 years) for definitive radiotherapy. 
 
 
1.9 Guidelines 
Medical guidelines (also called clinical guidelines) are documents providing consensus 
statements on best practice concerning specific areas of healthcare. Guidelines should 
evaluate the highest quality evidence available and discuss it in relation to prevention, 
diagnosis, treatment, prognosis and aftercare. The benefits from using guidelines are 
standardization of medical care and provision of the best available practice to unselected 
patients. Guidelines are not intended to replace individual treatment decisions. However, the 
considerations leading to management decisions deviating from guidelines should be recorded 
in the medical record. 
 Medical guidelines in oncology are developed for PCa patients, some as a result of an 
international consensus and some at national or hospital level [50]. The EAU PCa guidelines 
were first published in 2001, with updated versions in 2003, 2005, 2007, 2009 (full revision), 
2010 and 2011. The American Urological Association (AUA) published “Report on the 
Management of Clinically Localized Prostate Cancer” in 1995 [51], with total revision in 
2007 and an update in 2009. The main activity of the organization National Comprehensive 
Cancer Network (NCCN) is to develop clinical guidelines in oncology. NCCN is a 
cooperative organization of twenty-one cancer centers in the United States, most of which are 
designated as comprehensive cancer centers. Guidelines for specific cancer sites are free of 
charge and accessible from the NCCN’s website. The NCCN guidelines for PCa were first 
developed in 1995 and are updated annually. In Norway national guidelines for PCa were 
published in 2009 and at the time the patients in this thesis were diagnosed and treated, only 
the EAU guidelines from 2003 were relevant.   
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1.10 Treatment 
 
1.10.1 Treatment with curative versus palliative intention  
Localized and locally advanced PCa (from now collectively referred to as localized) (T1-3, 
N0-X, M0) are considered to be potentially curable. The decision whether or not to give 
curative treatment for localized PCa depended in 2004 upon the responsible physician’s 
evaluation of life expectancy (age and co-morbidity) and patients’ preferences. According to 
EAU guidelines from 2003 a life expectancy of at least 10 years was recommended if curative 
therapy was to be offered [38]. In 2004-2005 standard curative treatment modalities for 
localized PCa were RP and definitive radiotherapy, the latter with or without neoadjuvant 
and/or adjuvant [(neo)adjuvant] androgen deprivation therapy (ADT). The risk of dying from 
a diagnosed localized PCa for men older than 70 years decreases with increasing co-morbidity 
and age [33] and careful considerations as to treatment benefits are emphasized in the EAU 
guidelines with no rigid limits. In 2004 most clinicians would consider patients with N+ 
disease to be beyond curability, this view being reflected in Paper I, recognizing the later 
years’ gradual change of this principal view [52-54].  
 Men with metastatic PCa can be offered palliative treatment with the intention to 
prolong life and relieve symptoms, but without attempting to cure the disease. Palliative 
treatment can for example be a trans-urethral resection of the prostate (TUR-P) to relieve 
urinary-obstructive symptoms, low dose radiotherapy to relieve pain from metastases or 
hormonal treatment to delay disease progression. Palliative treatment is not further described, 
as this thesis mainly concerns men with non-metastatic PCa.  
 
1.10.2 Conservative management 
In the current thesis conservative management of PCa is divided into watchful waiting and 
active surveillance. Watchful waiting is offered patients where a decision is made not to 
provide curative treatment, but to initiate palliative therapy at the time of eventual 
progression. The indication for watchful waiting can for example be high age and/or co-
morbidity. The active surveillance group is principally different from the watchful waiting 
group as it consists of men who are considered to have “insignificant PCa” at the time of 
diagnosis. A decision is made to postpone curative treatment until the disease shows signs of 
progression. Indication for active surveillance is usually favorable prognostic factors 
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combined with a small tumor volume and informed consent from the patient. In 2004 active 
surveillance was not implemented as a routine curative treatment strategy in Norway, but 
could occasionally be used. The separation into two types of conservative management is 
dependent upon knowledge of the treatment decision process, as both groups consist of 
patients with localized PCa.  
 
 
1.10.3 Radical prostatectomy 
RP is the surgical removal of the prostate gland with tumor-free margins usually including the 
seminal vesicles. Thereafter the urethra is reattached to the bladder neck. Depending on the 
extent of the tumor the surgeon might also remove the regional lymph nodes to perform a 
histopathological examination [55]. In 2004 regional lymph node dissection was in Norway 
confined to the obturatory lymph nodes. The outcome concerning adverse effects after RP 
depends upon the anatomy of the patient, the skills of the surgeon and his/her team and might 
also be influenced by the surgical technique [56]. At the discretion of the operating surgeon 
unilateral or bilateral nerve sparing technique can be applied to preserve nerves important for 
erectile and urinary function. 
In Norway the most common surgical procedure for RP in 2004/2005 was the 
retropubic approach. In 2004 two Norwegian hospitals had started to perform laparoscopic RP 
and one hospital introduced robot-assisted laparoscopic RP in December 2004. 
 
1.10.4 Definitive radiotherapy 
Definitive radiotherapy is an alternative to RP and is often combined with ADT in patients 
with high-risk PCa. Definitive radiotherapy can be applied as external radiotherapy, 
brachytherapy or as a combination. The gold standard for definitive radiotherapy is three-
dimensional conformal radiotherapy as much as possible sparing the rectum and the bladder. 
The radiation series are normally given over 7-8 weeks, five days a week. PCa cells are 
relatively radio-resistant [57] and high doses have to be applied ranging from 70-78 Gray 
(Gy) in 2 Gy fractions. Dose escalation can reduce the risk of biochemical failure [58, 59] and 
improve survival [60]. The innovation of intensity modulated radiotherapy enables a more 
complex distribution of radiation within the treatment fields and helps to minimize radiation 
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dose to organs at risk, such as bladder and rectum [61]. In Norway three-dimensional 
conformal radiotherapy was the mainstay treatment in the period of study and is still standard 
treatment today. The usual practice is to apply an initial dose of 46-50 Gy to a larger volume 
with risk of tumor growth, for example the true pelvis, and a higher dose to the prostate itself 
(boost) [6]. Low-dose rate brachytherapy with iodine 131 was not offered at any Norwegian 
hospital in the period of study. High-dose rate brachytherapy combined with external 
radiotherapy was introduced in December 2004 [62]. 
1.10.5 Hormonal therapy 
As PCa cells are dependent upon the availability of androgens, their proliferation can be 
delayed and even stopped if the androgens, mainly testosterone, are removed from the blood 
stream. Even regression of existing tumor lesion can be observed during ADT. Alternatively 
one can inhibit the cellular uptake of testosterone by antiandrogens. Antiandrogens prevent 
the binding of circulating testosterone to the androgen receptor and thus remove androgen 
stimulation of the PCa cell. Removal of testosterone can be done either by surgical or medical 
castration, the latter causing discontinuation of the testicular testosterone production. The 
most common medication is the application of gonadotropin-releasing hormone agonists(Gn-
RH-agonists) also called luteinizing hormone releasing hormone-analogs (LHRH-analogs) 
which prevent the production of luteinizing hormone in the pituitary gland with subsequent 
termination of testosterone production [18].  
A randomized trial has concluded that patients with locally advanced PCa benefit from 
treatment with LHRH-analogs combined with definitive radiotherapy [63]. This combination 
has become the standard treatment for locally advanced PCa. Radiotherapy combined with 
(neo)adjuvant LHRH-analogs for six months has proven to be superior with respect to 
survival compared to definitive radiotherapy as monotherapy (RAD) in localized PCa, 
excluding low-risk patients [64]. However, the optimal duration of LHRH-treatment for PCa 
risk-categories is not evaluated in randomized trials. Neoadjuvant ADT can reduce the pre-
radiotherapy target volume and reduce the radiation field thus sparing adjacent tissue [65]. As 
the LHRH-analogs during the first weeks of their initiation are followed by a transient 
increase of testosterone production (flare), patients use anti-androgens two weeks prior to start 
of medical castration and for two weeks thereafter. A recent randomized trial has also shown 
that definitive radiotherapy combined with ADT is better that ADT alone [66].  
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Treatment with anti-androgens given adjuvant to definitive radiotherapy has been 
investigated in men with PCa confined to the prostate (T1-2, N0/x) and in men with locally 
advanced disease (T3-4, any N or any T, N+) [67, 68]. Anti-androgens are generally well 
tolerated as to adverse effects compared to castration and can be an alternative to LHRH-
analogs. No study directly compares outcomes after anti-androgens or LHRH-analogs in 
combination with definitive radiotherapy in patients with localized PCa.  
1.10.6 Survival and prognosis 
In the absence of large randomized trials, conclusive evidence of benefit from any curative 
treatment for localized PCa compared to conservative management is lacking. No curative 
treatment option for PCa had proved to be superior to the other in terms of survival [69] until 
Bill-Axelson et al [40] in 2005 reported from a randomized study that RP reduced PCa 
mortality and risk of metastases compared to “conservative management” in patients with 
localized PCa. However, the majority of patients in the study by Bill-Axelson et al was 
diagnosed in the pre-PSA era and is not representative for patients diagnosed today. Widmark 
et al found in a randomized study that definitive radiotherapy and (neo)adjuvant ADT halved 
the 10-year PCa specific mortality compared to ADT alone in men with locally advanced PCa 
(T3, N0, M0) [66]. A few population-based observational studies indicate that curatively 
treated men may have a higher chance of survival compared to conservatively managed 
patients with localized PCa [70, 71]. In spite of all uncertainty as to benefits in particular in 
low-risk patients curative treatment is today widely used. The 15-year mortality from low-risk 
screen detected PCa in men aged 55-74 years at diagnosis treated with conservative 
management has been estimated to be 1% [3]. The cancer specific survival after curative 
treatment in low-risk PCa is therefore predestined to be extremely good with a marginal 
benefit. Any 15-year survival benefit of curative treatment for low-risk PCa compared to 
conservative management has been estimated to be less than 1% [3]. To demonstrate survival 
benefits of PCa local treatment studies with long observation-time (10-12 years) are needed.  
Until results from randomized trials are presented, the reports from population-based 
observational studies can indicate treatment effect on survival. Observational studies 
estimating the overall 10-year PCa-specific survival show 95% confidence intervals (CIs) in 
the range 73-93% for prostatectomized patients, 61-83% for definitive radiotherapy and 66-
88% for conservative management [72] [71], with subgroups performing substantially 
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different according to clinical T-category, Gleason Score and preoperative PSA level. A 
nomogram reports the estimated risk of recurrence after PCa treatment. Nomograms which 
show estimated  risk of recurrence stratified by PSA level, Gleason Score and T-category 
have been developed both after RP [73, 74] and after radiotherapy [75] and reveal that some 
PCa tumors are highly aggressive. Nomograms to predict indolent PCa are also available [76]. 
However, nomograms do not evaluate the beneficial effect of treatment. With today’s 
evidence RP and definitive radiotherapy must be considered as equally effective, comparing 
patients with similar risk-groups of PCa. 
There are two ongoing comparative randomized trials for localized PCa treatment. The 
Prostate Testing for Cancer and Treatment trial (ProtecT) [77] is performed in the United 
Kingdom and compares active surveillance, RP and definitive radiotherapy and will publish 
its main results in 2016 concerning effectiveness of PCa treatment in men with PSA detected 
disease. The Prostate Cancer Intervention versus Observation Trial (PIVOT) [78] compares 
watchful waiting with RP in PSA detected PCa diagnosed in the United States. The results 
from the PIVOT study have not yet been published in a peer-reviewed journal. Nevertheless, 
it cannot be ignored that the first findings from PIVOT were presented by Dr. Wilt in the 
plenary session of the 2011 annual meeting of AUA as late breaking news [79]. With the 
caution of referring to unpublished results the PIVOT study shows no survival benefit from 
RP in low PSA or low-risk early stage PCa compared to observation. In his presentation at 
AUA Wilt added:” Results suggest a benefit from surgery in men with higher PSA or higher 
risk of disease”. Unfortunately it is not possible to have an opinion on these findings as the 
study is not available for critical review. 
 
1.11 Registration and availability of data in national health registries
1.11.1 The Cancer Registry of Norway/Norwegian Prostate Cancer Registry 
All new cancer cases in Norway have been reported to the CRN by law since 1953. Main 
sources of information are the copies of all histological/cytological reports with a cancer 
diagnosis which are routinely sent to the CRN for registration. Additionally, completion of a 
case record form is required containing coded clinical information from the physician 
responsible for the cancer diagnosis of the patient. Cancer cases are registered by a person’s 
unique personal identification number which also allows linkage to other public registries. 
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Cancer incidents in the CRN are coded manually based on all available reports (clinical 
reports, pathology reports) which are visible for the coding personnel either as a paper copy or 
electronic version. Sometimes reports are missing and the diagnosis is registered the best 
possible way according to available sources. The CRN has focused on tumor status at the time 
of diagnosis and on initial treatment. Apart from time and cause of death the CRN does not 
contain systematically collected follow-up data on cancer recurrence, adverse effects or global 
quality of life (QoL). Initial treatment for PCa is routinely documented in broad terms (RP, 
radiotherapy, planned hormonal treatment). A sub-registry of the CRN contains 
individualized data concerning radiation therapy, provided by all radiotherapy units in 
Norway. The completeness of registered cancer cases in the CRN has been thoroughly 
documented and was estimated to be 99.8% for PCa in the period 2001-2005 [80]. 
 TNM status, PSA value and Gleason score are essential variables in PCa diagnostics 
and treatment. Before 2004 the case record form was the same for all cancer types and did not 
include prostate specific variables. The Gleason grading system was recommended by a 
World Health Organization (WHO) consensus already in 1993 [45] and in 2003 nearly all 
pathologists in Norway had converted to the Gleason system. The Gleason score was 
nevertheless only available from the scanned images of histopathological reports in the CRN, 
which was inconvenient for research purposes [81]. PSA value at diagnosis was not reported 
to the CRN. The increasing demand for clinically important data for this patient group led to 
the establishment of a Norwegian Prostate Cancer Registry (NoPCR). The purpose of the 
NoPCR was to provide improved report on the new PCa cases at diagnosis, but did not aim to 
provide follow-up data. The establishment of a sub-registry for PCa in 2004 represented a 
necessary innovation. With the establishment of NoPCR several clinically important PCa 
specific variables became available, such as T category, PSA level and Gleason score. In 
addition the new PCa specific case record form (Appendix A) contained improved registration 
of diagnostic examinations as well as performance status (at diagnosis). An additional field 
enabled the registration of major co-morbidity with impact on treatment decision, such as the 
presence of another cancer or dementia. The NoPCR aimed to separate men treated with 
conservative management into watchful waiting or active surveillance. In order to achieve the 
highest possible completeness of essential data, careful manual review of available reports 
sometimes provided missing information. By this task and multiple reminders to hospitals and 
pathology laboratories, registration in the CRN/NoPCR became as complete as possible for 
the first year. 
 . 
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1.11.2 The Norwegian Prescription Database 
The Norwegian Prescription Database (NorPD) was established on 1st of January 2004 and 
contains information on dispensed drugs prescribed in Norway. Records for each prescription 
contain several available variables such as product name, active ingredient and Anatomical 
Therapeutic Classification (ATC) code, prescription date, amount/size of prescription and a 
code for reimbursement purposes. For studies meeting the aims of NorPD individualized data 
can be released after application, in 2004 restricted to patients who have provided informed 
consent. 
1.12 Adverse effects and global quality of life after prostate cancer treatment 
The term health-related quality of life (HRQoL) refers to WHO’s definition of health; “A 
state of complete physical, mental, and social well-being not merely the absence of disease or 
infirmity” [82]. Measures of health and evaluation of health care should therefore include 
dimensions of physical, mental and social well-being, which is denoted as “generic QoL” or 
“global QoL” in this thesis. In addition to global QoL cancer patients might develop cancer 
specific adverse effects related to the type of malignancy or its treatment. Long-term adverse 
effects after cancer treatment can be explained as health problems starting during cancer 
treatment and persisting more than one year after treatment termination. Additionally, health 
problems caused by cancer or its treatment which arise one year or later after treatment are 
called late adverse effects. In this two year cross-sectional survey the terms late and long-term 
adverse effects are used similarly. Long-term adverse effects can impact on global QoL and 
both types of measures are important and should be assessed separately.  
As the prognosis for men with a localized PCa diagnosis is good, most men live for 
many years with the adverse effects after curative treatment. Today’s PCa patients are 
encouraged to take part in the process of choosing between treatment options with similar 
prognosis [83]. They are therefore interested in possible side effects. Erectile, urinary and 
bowel dysfunction are considered as “typical adverse effects” after curative treatment for PCa 
and each treatment modality is related to specific patterns of symptoms. Differences as to late 
adverse effects may therefore impact on patients’ final treatment decision. Conservative 
management might be an option for some men with low-risk PCa and may for some patients 
be the optimal strategy to avoid adverse effects and thereby preserving global QoL. However, 
this approach may result in psychological symptoms as uncertainty and mental stress [84, 85]. 
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Some of the symptoms described as treatment related adverse effects may also be experienced 
by PCa patients who never had treatment [86].  
 
1.12.1 Measurement of adverse effects and global quality of life 
Adverse effects and global QoL can be measured by an external observer or by the patient 
himself. In both situations validated instruments should be used. Examples of instruments 
based on an external observer are the Common Terminology Criteria for Adverse Events 
(CTCAE) [87] and the Radiation Therapy Oncology Group/European Organization for 
Research and Treatment of Cancer (RTOG/EORTC) scale [88]. Karlsdóttir et al used the 
RTOG instrument to study late gastrointestinal and genitourinary morbidity after three-
dimensional conformal radiotherapy for PCa [89]. The benefit of using an external observer 
can be better communication with patients about treatment related adverse effects. 
Studies have shown that subjectively experienced cancer related morbidity is best 
reported by the patient as physicians tend to underestimate morbidity as summarized in 
several review articles [90, 91]. Assessment of global QoL and disease specific symptoms are 
thus today mainly done by the patients themselves, requiring validated psychometrically 
tested instruments. A validated instrument is a questionnaire which by psychometric measures 
(factor analysis, reliability and validity testing) has proven to accurately measure what it 
aimed to do. A reliable instrument should for example reproduce similar results at repeated 
measurements. Instruments usually contain questions that are organized into scales of certain 
domains [92]. The responses in a multi-items domain should show a high grade of internal 
consistency, usually assessed by the Cronbach’s alpha coefficient which also is a type of 
reliability testing. Resulting values should range from 0.6 to 0.9 to avoid inconsistency (<0.6) 
or unnecessary item replication (>0.9). Clinicians usually use either a complete questionnaire 
package or a combination of instruments to assess global QoL and typical adverse effects. It is 
recommended to use validated instruments or at least select complete domains, and avoid the 
application of ad hoc questions as much as possible. Measurement of adverse effects can be 
reported as a score, or dichotomized into groups using clinically meaningful cutoff-values. 
Results from dichotomized scales are usually easier to communicate to patients (percentage of 
patients with a specific symptom) than results from scores which mirror severity. 
Global QoL instruments assess the patients own perception of their health status. 
Several validated instruments are available [93-96]. The Short Form Health Survey-36 (SF-
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36) and the Short Form Health Survey-12 (SF-12) instruments are universally applicable in 
the general population. Other instruments are disease specific such as the Functional 
Assessment of Cancer Therapy scale (FACT) and the EORTC QLQ-C30 scale, designed for 
cancer patients in general. SF-36, FACT and QLQ-C30 all contain a dimension of energy or 
vitality comparable to fatigue. For more comprehensive measurement of fatigue a separate 
fatigue-specific instrument is recommended.  
For localized PCa the most typical cancer-specific adverse effects are urinary, bowel 
and sexual dysfunction. According to some, but not all published studies adverse effects 
should generally be separated into function and bother [97]. Several validated instruments 
based on patient report of symptoms have been developed for PCa patients. The incidence and 
prevalence of  “typical adverse effects” is frequently documented in the literature, but the 
figures vary considerably in the absence of standardized methods for measuring and reporting 
these adverse effects as problematised in Bhatnagar et al’s review article [98]. Bhatnagar et al 
concludes that it is difficult to provide accurate estimations of risk of adverse effects due to 
biased patient selection and various study designs. The extensive use of curative therapy 
warrants standardized measures of adverse effects which enables comparison between 
treatment modalities and between populations. 
When evaluating QoL or even adverse effects after cancer treatment, response shift 
has to be accounted for [99]. Response shift concerns the impact life changes have on how a 
person perceives his or her health and QoL. For non-metastatic PCa patients response shift 
can cause gradual acceptance of treatment-related adverse effects and change of expectations 
as to global QoL. This would result in a relatively satisfying global QoL in spite of 
considerable adverse effects. It is even suggested that psychological adjustment in patients 
both lead to greater awareness and reporting of adverse effects, nevertheless with a 
maintained or elevated global QoL perception [100]. Quantification of response shift requires 
repeated measurements. 
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1.12.2 Global quality of life 
A study of Norwegian men representative for the general population showed that subjects of 
70 years or older had the lowest scores on all scales of the SF-36 except for mental health and 
vitality. Low education, not being married and report of a disease and/or current health 
problem were associated with lower score in all scales [101]. Based on the literature, men 
newly diagnosed with localized PCa in the PSA-era are in general healthy, reflected by a 
global QoL not different from that of the general age-matched population [102, 103]. 
However, studies report that global QoL declined from baseline both at one and three months 
following treatment [104, 105]. Approximately one year post-treatment global QoL had 
recovered to baseline in most cases regardless of treatment modality [104, 105]. However, 
little is known about the association between global QoL and “typical adverse effects” after 
PCa treatment. Presence of slight to moderate urinary, bowel or sexual dysfunctions are not 
necessarily associated with reduced global QoL [103], however in some studies they are 
[106]. An explanation for this inconsistency can be cultural variations concerning the 
importance of these functions for participation in daily and individually preferred activities. 
Response shift may also explain the insensitivity of global QoL to variations of typical 
adverse effects [99].  
 
1.12.3 Sexual dysfunction 
Sexual functioning is dependent upon both psychological and physiological factors. The most 
common sexual problems reported by American men aged 57-74 years are erectile 
dysfunction, early ejaculation, lack in sexual interest and anxiety of performance [107]. 
Erectile function is not synonym to, but a part of sexual function. However, in many studies 
of PCa patients only erectile function is reported. Erectile dysfunction is the condition defined 
as the persistent inability to attain and maintain penile erection sufficient for sexual 
intercourse [108]. Causes of erectile dysfunction can be hormonal deficiency, disorders of the 
nervous system, inadequate penile blood supply and psychological problems [109]. Some 
sexual problems increase with age, and based on published estimates 39-51% of men aged 65-
74 years suffer from erectile dysfunction. Major co-morbidity as diabetes and vascular disease 
contribute to sexual problems, in the general population, also increasing the prevalence of 
erectile dysfunction [107, 110]. The condition of the partner and the strength of the 
relationship can also play an important role for sexual functioning and may be altered after a 
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cancer diagnosis [111]. Decline in erectile function occurs both after RP and radiotherapy for 
PCa [112]. Further, the addition of LHRH-analogs has shown to be negatively associated with 
several domains of sexual function [113].  
Erectile dysfunction after RP is often related to the damage of nerves and blood 
vessels which lie close to the prostate and usually occurs shortly after the operation. Estimates 
of complete erectile dysfunction after RP range between 26% and 100% [114]. Erectile 
dysfunction present at one year after RP treatment can be considered permanent though slight 
improvement might occur during the second year [115]. A recently published paper from the 
Scandinavian Prostate Cancer Group study number 4 (SPCG-4) reports significantly higher 
erectile dysfunction rate among prostatectomized men compared to men assigned to 
observation, after a median follow-up of more than 12 years [116]. In a systematic literature 
review from 2006 it was found that after a bilateral nerve-sparing procedure erectile function 
is preserved in 31-86% of sexually active men with organ-confined disease [117]. 
Except for psychological impact gradually decreasing penile blood supply is believed 
to be the major reason for post-radiotherapy erectile dysfunction. The neurovascular bundles, 
the internal pudendal arteries and the proximal penile structures are exposed to radiation. Low 
doses of radiation to these structures cause slow destruction of tissue and development of 
fibrosis with narrowing of the arterial volume [118]. Estimates of complete erectile 
dysfunction after definitive radiotherapy range between 8% and 85% [114]. The sexual 
function after radiotherapy steadily decreases during the five years after PCa diagnosis [119, 
120]. The inclusion of men who received adjuvant hormonal therapy may obscure the results 
by increasing the occurrence of erectile dysfunction. 
The addition of (neo)adjuvant LHRH-analog treatment impairs erectile function in 
most patients by lowering testosterone needed for sexual functioning to a castrational level 
[121, 122]. Few PCa patients regain their baseline erectile function and sexual desire after 
radiotherapy combined with use of ADT, often concurrent with a slow recovery of 
testosterone level [123, 124]. Recovery of erectile function is, however, dependent upon age 
and the duration of ADT. Detailed studies of recovery of erectile function after short-term 
ADT and radiotherapy are rare. 
Treatment for erectile dysfunction is available such as PDE5-inhibitors, intracavernous 
injections and vacuum devices. Not all studies report if sexual function is measured with or 
without treatment for erectile dysfunction. PDE5-inhibitors have proven to be effective both 
after bilateral nerve-sparing RP [125] and after radiotherapy [126] though not for all patients.  
Overall 62% of men with bilateral nerve-sparing RP reported improved erection after 12 
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weeks of tadalafil, compared to 23% in the placebo group [125]. Successful intercourse was 
possible for 41% of patients in the RP group versus 19% in the placebo group. Incrocci et al 
found that 67% of men with erectile dysfunction reported improvement after six weeks of 
tadalafil use compared to 20% in the placebo group [126]. Successful intercourse was 
possible in 48% of radiotherapy patients and 9% of men in the placebo group. Many men with 
improvement in erectile function will therefore still be defined as having erectile dysfunction. 
Stephenson et al [127] found that about 50% of patients following treatment for localized PCa 
had used medication for erectile dysfunction during the five years after diagnosis and overall 
Sildenafil helped a lot in 12% of those who used it. 
1.12.4 Urinary dysfunction 
Urinary dysfunction is commonly reported after curative treatment for PCa and the nature of 
the dysfunction varies with the type of treatment. Based on the available literature urinary 
incontinence should be separated from irritative-obstructive urinary symptoms [128-130]. 
Both urinary incontinence and irritative-obstructive urinary symptoms increase in prevalence 
with advancing age [131, 132]. Irritative-obstructive urinary symptoms are often related to 
enlargement of the prostate and are present in 29% of Norwegian men 55-69 years in 
moderate to severe degree [133]. Male urinary incontinence is usually urge-incontinence 
caused by an overactive bladder.  
Urinary incontinence is an acute/immediate and late adverse effect after RP with 
small, if any, increased risk after definitive radiotherapy [119, 134, 135]. Urinary 
incontinence after RP has its onset immediately after the operation with improvement during 
the first post-operative year [134]. Estimates of urinary incontinence after RP defined as daily 
leakage range from 16% to 24%, admittedly from published studies with widely different 
follow-up time [119, 134, 135]. The stabilization of urinary incontinence occurs around one 
year after RP with only slight improvement thereafter [115].  
Irritative-obstructive urinary symptoms, such as slow or difficult urination, are more 
frequently reported by men after radiotherapy compared to men after RP [119]. The irritative-
obstructive urinary symptoms after radiotherapy have gained far less attention than RP related 
urinary incontinence in the literature concerning acute and late adverse effects after primary 
treatment for localized PCa.  
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1.12.5 Bowel dysfunction 
Bowel dysfunction reported by PCa patients concerns fecal leakage, bowel urgency, chronic 
diarrhea, blood or mucus in stool, painful defecation, painful hemorrhoids, tenesmus and 
frequent defecation.  
Acute bowel dysfunction after definitive radiotherapy occurs early after treatment and 
is mainly caused by damage of the intestinal rectal mucosa [136]. This dysfunction may 
worsen during the first post-treatment months with gradual recovery thereafter. Bowel 
dysfunction is significantly worse six months post-treatment compared to one year post-
treatment [115]. 
Onset of more long-lasting bowel dysfunction usually starts within two years after 
radiotherapy [115, 119]. In irradiated patients late bowel dysfunction is a consequence of 
radiation to the rectum and intestinal tract located in the true pelvis. Increasing small vessel 
obliteration and development of fibrosis in the rectum/bowel wall are etiological factors of the 
late bowel dysfunction, together with radiation-induced nerve damage. The severity of bowel 
dysfunction after definitive radiotherapy is dependent upon the volume of treated rectum and 
the maximum radiation dose to the rectum [137].  
Bowel dysfunction after RP is rarely the focus of studies of adverse effects, probably 
because it seldom is a major problem for the patients. Post-treatment bowel dysfunction 
(rectal bleeding, abdominal pain or cramps, loose stools and bowel urgency) was  
significantly worse after definitive radiotherapy than after RP both 6 months and 12 months 
after diagnosis [134]. In the previous study bowel urgency approximately one year after 
diagnosis was present in 26-30% of radiotherapy patients and 6-7% of RP patients [134]. 
Potosky et al [112] found the difference to be smaller, as 30.5% of radiotherapy and 16.1% of 
RP patients reported bowel urgency. Estimated bowel urgency after twelve months was 19% 
after radiotherapy and 6% after RP in a publication by Talcott et al with yet another definition 
of the symptom and other criteria for patient selection [138]. 
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1.12.6 Fatigue and chronic fatigue 
Cancer-related fatigue has been defined by the NCCN as: "a distressing persistent, subjective 
sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or 
cancer treatment that is not proportional to recent activity and interferes with usual 
functioning." NCCN summarizes the problem as follows: “Persistent cancer-related fatigue 
affects quality of life, as cancer patients become too tired to fully participate in the roles and 
activities that make life meaningful.” Fatigue has been reported as the most distressing late 
adverse effect after cancer and its treatment [139]. It has been estimated that fatigue during a 
course of definitive radiotherapy may be experienced in as many as 90% of all cancer 
patients. However, and more important, fatigue becomes a chronic condition in about 30% of 
cancer survivors [140]. 
Several instruments for assessing fatigue are available [141-147]. If fatigue has 
persisted for six months or more it can bee defined as chronic fatigue (CF) [146]. Most fatigue 
instruments do not include the duration of fatigue and only measure the presence of 
severe/moderate fatigue. Though the concepts of fatigue and CF are associated, NCCN states 
that it is the persistent fatigue which affects QoL contrary to acute short-lasting fatigue. 
Measurements of fatigue should therefore include a measure of the duration.  
The etiology of fatigue in cancer patients is unknown. As fatigue is not limited to one 
specific cancer type or treatment it is probably a result of multiple factors. Several 
mechanisms have been proposed to be important for the development of fatigue in cancer 
patients. The activation of pro-inflammatory cytokines is suggested to play a role in the onset 
of fatigue [148] and elevated levels of some cytokines are associated with fatigue in cancer 
patients [149]. Pro-inflammatory cytokines are thought to signal the central nervous system 
with subsequent behavioral effects as reduced activity, increased pain sensitivity and 
cognitive alterations [150]. Functioning of the hypothalamic-pituitary-adrenal (HPA) axis is 
necessary for release of cortisol and mobilization of energy resources when exposed to stress. 
Dysregulation of the HPA-axis may play a role in the chronic inflammatory process [148]. In 
extension to this hypothesis, disturbance of the intestinal tract may have causal relationship 
with CF, and both altered intestinal microbiota and dysfunction in the mucosal barrier is 
observed in fatigued persons [151-153]. In brief, any inflammation can increase the 
permeability of the gut membrane to lipopolysaccharides produced by gram negative bacteria, 
which may again increase the production of pro-inflammatory cytokines. Several cancer 
 32
therapies can possibly cause intestinal inflammation; especially relevant for localized PCa is 
the use of radiation therapy to the pelvis [154]. 
In the general Norwegian male population CF was positively correlated with older age 
and was reported by 16.8% of men older than 60 years [155]. In the same paper by Loge et al, 
lower education, being unemployed or having a disease and/or current health problem were 
associated with increased risk of CF among men. The high prevalence of CF in the general 
population is important for the interpretation of the symptom prevalence in PCa populations. 
Before 2005 fatigue in PCa patients was mostly identified as a complication during 
ADT [156, 157] often described as “loss of vitality” or “energy loss”. Fatigue was rarely 
reported as a late adverse effect after RP and definitive radiotherapy for localized disease. 
Largely, existing studies concerning fatigue and definitive radiotherapy focused on the 
presence of fatigue only during radiotherapy treatment [158]. Nevertheless, the persistence of 
increased fatigue twelve months after radiotherapy was reported by Beard et al, already in 
1997 [159]. An often cited study comparing long-term morbidity and QoL among RP and 
definitive radiotherapy patients showed that fatigue was common in both treatment groups 
with a prevalence of 10% and 15%, respectively [103]. Severe fatigue as a long-term effect 
after definitive radiotherapy (> 1 year after radiotherapy) was also reported by Vordermark et 
al in 2002 [160] who found the prevalence of severe fatigue among men with definitive or 
post-operative radiotherapy to be 18.7% after a median of 2.1 years, measured with the Brief 
Fatigue Inventory [147]. Weaknesses with these studies are that additional treatment such as 
ADT was not taken into account and that the studies include patients with recurrence. There is 
no doubt that fatigue can occur during long-lasting ADT, but whether fatigue persists after 
discontinuation of adjuvant ADT and for how long time is not assessed in the literature.  
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1.13 Status at the start of the thesis 
1. Since 2000 there was an increasing recognition among Norwegian urologists 
and oncologists that the conventional CRN registration of recently diagnosed 
PCa had become insufficient for clinical research. New from January 1st 2004 
is the NoPCR registry which should offer new opportunities to study patients 
using more modern principles of risk-categorization related to treatment.  
2. Fatigue is recognized as a frequent long-term effect after cancer, but few 
studies are performed in men with curative treatment for PCa. The literature 
suggested that fatigue was more common after definitive radiotherapy than 
after RP, however the studies were methodologically weak as they included 
patients with (neo)adjuvant ADT.  
3. Published estimates of adverse effects and global QoL vary considerably. No 
population-based Norwegian estimates are available. Further, published figures 
of prevalence of adverse effects are confounded by age and co-morbidity as 
well as (neo)adjuvant hormone treatment, cancer recurrence or use of PDE5-
inhibitors. The relationship between adverse effects and global QoL is rarely 
investigated. 

 34
Chapter 2: The current thesis 
2.1 Background 
In 2003 an interdisciplinary group of PCa experts in Norway formed the National Program for 
Prostate Cancer (NPPC) with the agenda to work out a national strategy for research on PCa. 
The establishment of the NoPCR was the first result of NPPC’s strategy. NoPCR was 
established and running by January 2004. The CRN/NoPCR could from 2004 theoretically 
inform about the annual number of RP and radiotherapy courses, but research had to 
document the quality of this registry and indicate eventual future improvement strategies. In 
particular it seemed necessary to assess whether the additional registration allowed allocation 
of patients into risk-groups, requiring different treatment strategies and the treatment 
adherence to the existing EAU guidelines.   
In 2006 the medical literature provided much information about the “typical adverse 
effects” after RP and definitive radiotherapy, the latter with or without ADT. Except for one 
study addressing such patients [103] little information was available for Norwegian patients 
treated in the first decade of the 21st century. At the same time, more and more Norwegian 
men planned for RP or definitive radiotherapy asked for evidence-based information about 
adverse effects and global QoL to be expected after their treatment.  
Further, the prevalence of CF was not sufficiently explored in patients during or after 
curative treatment for PCa, though post-cancer fatigue had been recognized as a frequent 
long-term effect in several groups of cancer patients with significant impact on global QoL.  
Finally, on the background of the growing interest in active surveillance and watchful 
waiting it was desirable to achieve more information on “typical adverse effects” in patients 
without local curative treatment.  
In summary, there was an increasing demand for follow-up data on adverse effects and 
global QoL data for patients with localized PCa. As a joined decision of the NPPC and the 
Norwegian Urological Cancer Group (NUCG) a cross-sectional survey among PCa survivors 
in the 2004 cohort was sent out in October 2006.  
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2.2 Study aims 
Based on the background outlined above the thesis had the following aims: 
 
I. To perform a quality control of the NoPCR established in 2004, aiming to achieve most 
complete categorization of the patients into risk-groups with therapeutic consequences. A 
particular question of interest was whether patients could be identified who should be offered 
curative treatment. A secondary aim was to monitor to what degree recommendations were 
followed as published in the 2003 EAU guidelines with emphasis on patients who were 
candidates for curative treatment.  
 
II. In a cross-sectional study to investigate the prevalence of CF in PCa patients after RP and 
RAD as monotherapy and to investigate the associations between CF and medical and 
psychosocial variables.  
 
III. To assess the post radiotherapy prevalence of CF in patients with ongoing hormonal 
therapy compared to patients who had discontinued hormonal therapy at the time of the 
survey. Secondly, we aimed to investigate associations between CF and selected medical and 
psychosocial variables. 
 
IV. To provide population-based two year estimates of “typical adverse effects”, such as 
urinary, bowel and sexual dysfunction in non-metastatic recurrence-free PCa patients in 
relation to treatment modality also including a group without treatment. Secondly we aimed to 
describe associations between these “typical adverse effects” and global QoL, to study 
patients’ use of medication for erectile dysfunction and the relation between such use and 
global QoL. 
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2.3 Materials and methods
 
2.3.1 Data sources 
National population-based postal survey 
In 2005 the NPPC and the NUCG agreed to perform a cross-sectional survey among PCa 
survivors diagnosed in 2004 and registered in the NoPCR. The survey aimed to study “typical 
adverse effects” and global QoL and was designed by using data from the NoPCR and the 
NorPD. The survey was designed in 2005 as a questionnaire based cross-sectional study. 
Eligible patients were identified by the CRN and were per mail invited to complete a 
questionnaire dealing with sociodemographic items and typical adverse effects as well as 
global QoL and fatigue. After about one year of preparation the study patients were invited by 
mail by their responsible physician to participate in the survey if they fulfilled the following 
eligibility criteria: 
 Alive in 2006 
 Considered to be approachable by the responsible physician who approved a list of 
names with possible participants 
 Not diagnosed after a cystoprostatectomy 
 The patients did not have an uncertain diagnose or were under evaluation 
 Known address in Norway 
Fourteen private urologists and 41 public hospitals accepted the offer to participate with their 
patients. Lists of eligible patients were sent to each institution and the patients were invited to 
participate in the national postal survey by a physician at the health-institution where the 
patient was first diagnosed. Twenty institutions contacted 50 patients, 14 institutions 
contacted between 20-49 patients and 21 institutions contacted less than 20 patients. The 
patients received a letter of information together with the questionnaire, and were also asked 
to sign a written informed consent if they wanted to participate in the survey. The survey 
responses were scanned and digitally read. One reminder was sent out to non-compliant 
patients. 2998 patients were initially invited to participate and of these 34 men either had died 
during the distribution process or were reconsidered by their responsible physician not to be 
eligible before the reminder was sent out. The invitation process and responses are depicted in 
Figure 2.  
 For consenting patients, the results from the questionnaire were connected to data 
from the CRN/NoPCR and the NorPD, based on the unique personal identification number.  
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Participants after 1st 
invitation, N=1774    
(11 not aware of PCa) 
Not invited to participate in survey, N=836 
Dead before survey, N=742 
Cystoprostatectomy, N=23 
Uncertain diagnose/under 
evaluation, N=26 
Emigrated/no address, N=15 
Physicians choice, N=30 
Non-participants after 1st invitation, N=257 
Did not want/was not able to 
participate, N=207 
Not aware of PCa diagnosis, N=16 
Dead or excluded before reminder, 
N=34 
 
Diagnosed in 2004, N=3833 
     
           1st invitation, N=2998  
 
     Reminder, N=967 
   
Participants after 
reminder, N=419      
(1 not aware of PCa) 
Non-participants after reminder, N=546 
Did not want/was not able to 
participate, N=98 
Not aware of PCa diagnosis, N=5 
No response, N=443 
ᅛTotal participants, N=2193 ᅝTotal non-participants, N=803 
 
Figure 2: Invitation of eligible patients and response to the invitation 
 
 
 
Data from the Cancer Registry of Norway/Norwegian Prostate Cancer Registry 
The following patient and cancer “baseline” data were collected from the CRN/NoPCR: date 
of diagnosis, age at diagnosis, curative treatment (RP or definitive radiotherapy), other 
treatment, date of treatment start, PSA at diagnosis, Gleason score from biopsy, clinical TNM 
category, Eastern Cooperative Oncology Group (ECOG) performance-status at diagnosis, and 
other cancer diagnosis. High-dose rate brachytherapy combined with external radiotherapy 
was introduced in 2004 [62], but is in this thesis not separated from conventional 
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radiotherapy. The data files were provided in June 2008 and contain combined information 
reported to the CRN and NoPCR by this date, which can be different from equivalent data 
extracted at another date because the registry is continuously updated. The interpretation and 
reporting of the CRN data are the sole responsibility of the authors, and no endorsement by 
the CRN is intended nor should be inferred 
  
Data from the Norwegian Prescription Database 
In paper II variables from the NorPD were essential for identification of hormone-naive men. 
All patients with any prescription of PCa related use of hormones between diagnosis and the 
survey were excluded. Such differentiation could not be done for non-participants as NorPD 
data were not released for these men. In paper III and IV prescription data from the NorPD 
identified patients with continuous use of LHRH-analogs and were used to assess the duration 
of such treatment. Further, in paper IV patients with prescribed medication for erectile 
dysfunction were identified, including use of PDE5 inhibitors, Alprostadil urethral sticks and 
Papaverin injections.  
 
 
2.3.2 Study populations 
Paper I (Population of men with a prostate cancer diagnosis from 2004) 
In this descriptive study all patients with a PCa diagnosis in 2004 were included regardless of 
the basis of the diagnosis, tumor extent or missing data. The data file was extracted from the 
CRN and NoPCR in June 2008. Patients who were diagnosed by autopsy, death certificate 
only or cystoprostatectomy were excluded from analyses of initial treatment as this could not 
be followed by a therapeutic treatment decision (Figure 3). Patients entitled as “candidates for 
curative treatment” met the following criteria: T1-3 N0-X M0 category, PSA level100 
ng/mL, any Gleason score, age 75 years at diagnosis, ECOG performance status 0-1, no 
other cancer, no known co-morbidity at diagnosis as assessed from a voluntary commentary 
field. Initial local treatment was defined if RP was performed within six months or definitive 
radiotherapy was performed within 14 months.
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N=3833 
Prostate cancer diagnosis 
in 2004
n=1650 (43%) 
Candidates for 
curative treatment 
n=295 (8%) 
Basic 
diagnostics 
missing 
n=833 (22%) 
Advanced disease
     
     
n=966 (25%) 
Ineligibility criteria for 
curative treatment* 
n=89 (2%) 
Not assessed for initial treatment 
Reported by death certificate only: n=22 
    Incidental finding by autopsy: n=30 
    Incidental finding by cystoprostatectomy: n=37
N=3744
Assessed for initial treatment
 
*highage(>75years),ECOGperformancestatus2orperformancestatusmissing,othercancer,
seriouscomorbidityreported
Figure 3: Patients diagnosed in 2004 
Paper II-IV (PCa survivors participating in the national survey) 
The survey conducted in October 2006 primarily included all eligible survivors from the 2004 
cohort. The focus of the current thesis was restricted to compliant non-metastatic patients 
belonging to defined treatment categories and without other adjuvant treatment or evidence of 
recurrence (Table 2). The use of adjuvant or salvage treatment was known from the 
CRN/NoPCR, the CRN’s radiotherapy registry and by linkage to the NorPD. Further, study 
populations were restricted to survey participants with complete data on relevant instruments.  
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Table 2: Relevant treatment groups for papers II-IV  
 RP RAD 
hormone-
naïve 
RAD+ADT* with 
discontinued hormone 
treatment 
RAD+ADT* with 
ongoing hormone 
treatment 
No treatment 
Paper II ᅜ ᅜ  
Paper III ᅜ ᅜ ᅜ
Paper IV ᅜ ᅜ ᅜ ᅜ
*RAD+ADT: definitive radiotherapy with (neo)adjuvant hormone treatment 
 
Paper II 
Among survey participants with a valid Fatigue Questionnaire (FQ), PCa patients treated with 
RP or RAD who never had received ADT or orchiectomy were included in the study. No 
supplementary PCa treatment was received in addition to the RP or RAD treatment before the 
survey. Twelve months or more had elapsed between start of initial curative treatment and the 
survey. A control group from the Norwegian male population aged  60 years was used for 
comparison [155].  
 
Paper III 
Among survey participants with a valid FQ, patients were eligible if they had radiotherapy 
with (neo)adjuvant ADT (RADHT). Eligible patients started continuous treatment with 
LHRH-analogs (with or without simultaneous anti-androgens) up to eight months prior to 
start of radiotherapy. Men still using LHRH-analogs at the time of the survey (HTcont) were 
separated from men who had their last prescription of LHRH-analogs at least 6 months before 
the survey (HTdis). Any other ADT-use led to exclusion, e.g. those who had intermittent use 
of LHRH-analogs or those who started anti-androgen monotherapy after discontinuation of 
LHRH-analogs. Start and end of LHRH-analog treatment was estimated by using the date of 
the first prescription and the amount of prescribed medication (1 or 3 month’s depot effect), 
as documented in the NorPD. The previously described hormone-naïve RAD patients were 
included as a control group. 
  
Paper IV 
The study was performed among study participants with a valid SF-12 who were “candidates 
for curative treatment”, as defined in Paper I.  Further, eligible patients had to belong to one 
 41
of the following treatment categories of initial treatment without any other PCa specific 
therapy: 1) No treatment, 2) RP, 3) RAD without hormones, 4) RADHT with hormone 
therapy of 3-24 months duration, the last three-month LHRH-depot injection prescribed at 
least 6 months prior to the survey. Start of the defined local treatment had to be one year prior 
to the survey and all treatment had to be discontinued before the survey. For the “No 
treatment” group the date of diagnosis represented the start of treatment.   
 
2.3.3 Measures and instruments 
In general, the design of the final questionnaire was a joined task of the project group of 
NPPC and it is rendered in its entirety in Appendix B. As it was necessary to combine 
different views and priorities of members in the NPPC, the project leader could not always 
meet the requirement of using only validated and formally translated items or domains. 
However, in principal the questionnaire reflects this intention. The population-based survey 
thus contains selected items from previously published validated questionnaires and some 
supplementary study specific questions.  
The Short-Form Health Survey 12 
Global QoL was measured by the physical and mental summary scores of the  validated 
instrument SF-12 [94]. The scores of PCS and MCS were transformed by linear T-
transformation and standardized to have a mean score of 50 and a standard deviation of 10. In 
paper II we used the SF-12 single item of bodily pain. In paper IV low global QoL was 
defined as having a PCS and/or MCS of 40 or below. The SF-12 has previously been 
translated to Norwegian, and validated in a Norwegian population [161]. 
 
Urinary adverse effects 
The International Prostate Symptom Score (IPSS) 
IPSS measures irritative-obstructive urinary symptoms [162, 163]. Three IPSS categories 
were defined using recommended cut-off levels; none/mildly symptomatic (0-7), moderately 
symptomatic (8-19) and severely symptomatic (20-35). In paper IV the categories were 
further dichotomized (0: no symptoms/mildly symptomatic and 1: moderately or severely 
symptomatic). The IPSS has previously been translated to Norwegian [133]. 
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Urinary incontinence 
Urinary incontinence was defined as “leaking urine at least once a day”. In paper II and III 
irritative symptoms and urinary incontinence were combined in a variable called “urinary 
dysfunction”, while in paper IV the two items were analyzed separately.  
 
Bowel dysfunction 
Intestinal irritative symptoms 
Intestinal irritative symptoms were defined as having at least one of the following traits: 1) 
defecation 3 times a day, 2) at least 50% of the times; diarrhea, blood or mucus in stool or 
painful defecation, 3) 2 times a week cramps or fecal urgency.   
 
Fecal leakage 
Presence of fecal leakage was defined as fecal leakage once a week or more. In paper II and 
III intestinal irritative symptoms and fecal leakage were combined in a variable called 
“intestinal dysfunction”. In paper IV the two items were analyzed as separate variables. 
 
The Brief Male Sexual Function Inventory (BSFI)
BSFI is an eleven-item inventory that assesses five dimensions of sexual function: drive, 
erection, ejaculation, problem assessment and overall satisfaction with sexual life [164]. 
Mykletun et al have shown that BSFI can serve as an overall measure of sexuality, excluding 
overall satisfaction [165]. The instrument is translated into Norwegian and is validated [165]. 
The items are scored on a five-point Likert-scale and the total score ranges from 0-40. A 
higher BSFI total score implies a better sexual function. The BSFI was used in paper II and III 
as a continuous variable. In paper IV we used the following cut-off levels to define 
“Caseness” for drive and erection; poor sexual drive 3 and poor erectile function 7 [166].  
 
The Fatigue Questionnaire
FQ evaluates physical fatigue (seven items) and mental fatigue (four items) [146]. Total 
Fatigue Score is the sum of all eleven items. Items are measured on a four-point Likert-scale 
(0-3) where higher scores imply more fatigue. Physical, mental and total fatigue ranges from 
0-21, 0-12 and 0-33, respectively. Two questions concern the duration of the fatigue. 
Caseness of CF is defined as the sum-score of 4 after dichotomization of the FQ symptom 
scores (0-1=0, 2-3=1) and with duration of six months or more. The FQ was used in paper II 
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and III and used the translation by Loge et al who validated the FQ and provided normative 
data in a Norwegian representative sample in 1997 [155].  
 
Eysenck Personality Questionnaire (EPQ-18) 
As symptom-reporting and physical complaints may be influenced by a person’s neuroticism, 
we included a measure of this personality trait. Neuroticism describes if a person generally 
feels anxious or safe. People with a high degree of neuroticism are likely to interpret even 
normal situations as problematic or threatening [167]. An abbreviated version of the Eysenck 
Personality Questionnaire (EPQ-18) measured neuroticism [168]. The EPQ-18 was translated 
and validated in a Norwegian population in 1990 [169]. Six items comprise the personality 
trait neuroticism (range 0-6) which covers the dimension from feeling safe (score 0) to feeling 
maximally nervous (score 6). In paper II and III we defined “low neuroticism” as score 0-4 
and “high neuroticism” as score 5-6 [170]. In paper IV we categorized neuroticism into “low 
neuroticism” (score 0-1) “moderate neuroticism” (score 2-3) and “high neuroticism” (score 4-
6).  
 
Missing responses 
Missing responses in the questionnaire were replaced with the mean value within a domain if 
at least half of the items were valid. Otherwise, domain scores were considered as missing 
[171]. 
 
2.3.4 Ethical considerations 
All parts of the present thesis were approved by the Regional Committee for Medical 
Research Ethics, the protocol review of committee of the Norwegian Radium Hospital, and 
the Norwegian Data Inspectorate. All participants in the national survey provided written 
informed consent including permission to the use of their NorPD data.   
An ethical challenge occurred while collecting data for the survey. After the first 
invitation of 2998 patients 33 persons (1%) responded that they did not have a PCa diagnosis. 
The physicians at the medical centers where the PCa was diagnosed and who approved their 
participation were informed of the situation. We recognized that the problem mostly 
concerned patients with “insignificant” PCa (micro focus). Before a reminder was posted to 
non-responders we provided a list of these patients to the responsible doctor and asked for a 
confirmation that the patients were informed of their PCa diagnosis. The fact that some men 
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were not informed of their “insignificant” PCa or had not perceived it as a PCa diagnosis was 
an unforeseen problem. In addition, other studies have shown that some cancer patients might 
deny their diagnosis [172]. In either way it was stressful for these men to be contacted in 
relation to a PCa diagnosis and every attempt should be made to avoid such situations in the 
future. Our experiences should be a reminder for other groups working with similar studies to 
be precautious when contacting persons identified through a health registry. 
2.3.5 Statistics 
Median and range were calculated to describe data with skewed distributions. Mean and 
standard deviation were calculated to describe data with normal distributions. Continuous 
variables were compared using t-tests and analysis of variance (ANOVA) if normally 
distributed and Mann-Whitney Wilcoxon if skewed. Categorical variables were analyzed with 
Chi-square tests. Multivariate analyses were performed using logistic regression analysis. The 
strength of an association was expressed as an odds ratio with a 95% CI. All tests were two-
sided. The analyses were performed using versions of the Statistical Package for Social 
Science (SPSS version 15 and PASW version 18, Chicago, IL) 
 
 
2.4. Main findings 
2.4.1 Paper I
In this paper we analyzed the compliance to the NoPCR and assessed initial treatment of men 
with a PCa diagnosis in Norway in 2004.  
 The first year experience with registration of prognostic and therapeutic variables in 
the NoPCR showed a compliance-rate of 96%, admittedly after sending many reminders to 
the hospitals. To achieve as high completeness as possible interpretation of all available 
information was essential, even though such data were not always submitted to the CRN on 
structured case record forms. Nevertheless, missing information caused that 295 non-
metastatic patients could not be classified to risk-groups (Table 3). Forty patients with basic 
diagnostics missing received definite curative treatment. 
 Of 3833 patients diagnosed in 2004 we defined 1650 men as candidates for curative 
treatment (Figure 3). A total of 966 patients were ineligible as candidates for curative 
treatment due to old age, poor performance status, major co-morbidity or other cancer and 
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85% of these were categorized as intermediate or high-risk patients. Of these 966 ineligible 
patients, 73 (8%) did receive definite curative treatment.  
 In total 1022 (62%) of CurCands received curative treatment (RP: 360, definitive 
radiotherapy: 662). RP was administered in 18 different hospitals (1-10 prostatectomies: 8 
hospitals. 11-24 prostatectomies: 3 hospitals. 25 prostatectomies: 7 hospitals). Definitive 
radiotherapy was administered in seven different hospitals. Among CurCands 500 (30%), 453 
(27%) and 697 (42%) patients were categorized to the low-, intermediate- and high-risk 
group, respectively. The proportions curatively treated patients were 57%, 68% and 61% for 
the low-, intermediate and high-risk group, respectively. In the low-risk group patients with 
T2 tumors had higher risk of receiving curative treatment than men with T1 tumors. In the 
intermediate- and high-risk groups the probability to undergo curative treatment significantly 
decreased with increasing PSA. In the two latter groups increased age also significantly 
reduced the probability of curative treatment.  
 
 
Table 3: Description of treatment and missing variables in 295 non-metastatic patients 
with missing basic diagnostics (PSA, Gleason score, T category) 
Patient descriptives Missing basic diagnostics 
N=295
Prognostic factors missing, N (%)  
   Missing PSA only 45 (15) 
   Missing Gleason Score only 100 (34) 
   Missing T category only 92 (31) 
   Missing two or more prognostic factors 58 (20) 
Curative treatment, N (%)  
   RP within 6 months 15 (5) 
   Definitive radiotherapy within 14 months 25 (8) 
 


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2.4.2 Compliance to the national survey (paper II-IV) 
In the current survey 2998 men were invited to answer the questionnaire in October 2006 and 
of these 73% (N=2194) participated. Compliers had median age 69 years [range: 44-94 years] 
and non-compliers had median age 74 years [42-96 years], p<0.001. Men aged 75 years had 
a compliance rate of 80%. The compliance rates for RP, definitive radiotherapy and 
CurCands, from Paper II-IV, were 87%, 85% and 78% respectively. The compliance rate was 
highest for men with non-metastatic disease compared to those with metastatic PCa or 
unknown metastasis status (Figure 4). 
 
 
 
 
 
Figure 4: Compliance rates to the national survey stratified for metastasis status. 
Numbers and proportions for compliers are given at the green section and non-
compliers at the blue section of the bars. 
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2.4.3 Paper II 
In this paper the prevalence of CF was compared in patients with RP or RAD as monotherapy 
more than one year after treatment start. We identified 521 patients with curative 
monotherapy (RP: 337, RAD: 184). RP patients were significantly younger at diagnosis 
compared to RAD patients (RAD: median 66 years, RP: median 62 years). RAD patients 
more often belonged to the intermediate or high-risk group (60%) compared to RP (47%). At 
survey co-morbidity and pain was reported by 55% and 60% of the RAD patients, 
respectively, compared to 39% and 44% in the RP group. The prevalence of urinary and 
intestinal dysfunction was 30% and 21% among RP patients and 21% and 48% among RAD, 
respectively. RAD patients had a significantly better sexual function compared to RP in 
unadjusted analyses.  
 Physical, mental and total fatigue was significantly higher in RAD patients 
compared to RP. The proportion of patients with CF was 13.4% after RP and 26.1% after 
RAD. In multivariate analyses patients after RAD had a doubled risk of CF compared to RP. 
Younger age, presence of high neuroticism, co-morbidity, pain, urinary and intestinal 
dysfunction were positively and significantly associated with increased risk of CF. Risk-group 
was not significantly associated with CF. The difference in CF between RP and RAD was 
largest in patients with the longest observation times.  
2.4.4 Paper III 
In this paper we investigated the prevalence and severity of CF in definitive radiotherapy 
patients with ongoing or discontinued (neo)adjuvant ADT. As control group we used the 
RAD group from Paper II. Of 239 consenting, evaluable patients treated with RADHT, 82 
were still on hormone therapy (HTcont) and 157 men had discontinued hormone treatment 
(HTdis) at the time of the survey.   
 In the HTcont group 19% and 80% of patients belonged to the intermediate- and 
high-risk group, respectively. This was significantly different from the HTdis group where 
27% and 64% belonged to the intermediate- and high-risk group, respectively (p<0.001). The 
median duration of (neo)adjuvant ADT was 27 months in HTcont and 6 months in HTdis 
patients (p<0.001). 
 Patients in the HTcont group had the highest prevalence of CF (39.0%) compared to 
22.3% in the HTdis group and 26.1% in the control group. In the adjusted analysis belonging 
to the HTcont group doubled the risk of CF compared to the hormone-naïve controls, whereas 
 48
men from the HTdis group had no elevated risk of CF. Younger age, presence of pain and 
high neuroticism as well as urinary, intestinal and sexual dysfunction increased the risk of CF. 
Exclusively looking at patients who had discontinued their LHRH-analog treatment, treatment 
duration >6 months, younger age and urinary, intestinal and sexual dysfunction increased the 
risk of CF.  

2.4.5 Paper IV 
This paper provides information on global QoL and prevalence of typical adverse effects in 
non-metastatic PCa patients who were candidates for curative treatment. After approximately 
two years since diagnosis totally 771 patients were eligible (NoTreat: 180, RP: 293, 
RADNoHT: 156 and RADHT: 142). NoTreat patients were oldest with median age 70 years 
compared to 62, 67 and 66 years in RP, RADNoHT and RADHT patients respectively. High-
risk PCa was significantly more common in RADHT (61%), compared to 23%, 12% and 16% 
in NoTreat, RP and RADNoHT respectively. The NoTreat and RADNoHT group presented 
the highest prevalence of co-morbidity at survey (53%) and RP patients the lowest (37%). 
Prostatectomized men reported significantly more urinary incontinence (24%), but the lowest 
prevalence of irritative-obstructive urinary symptoms (23%) compared to the other treatment 
groups (Table 4). The two groups of irradiated men reported more irritative intestinal 
symptoms (RADNoHT: 47%, RADHT: 42%) and fecal leakage (14%) compared with RP and 
the NoTreat group. A rather high proportion of men from the NoTreat group experienced 
urinary incontinence (13%) and irritative-obstructive urinary symptoms (50%). Poor erectile 
function was common in all treatment groups ranging from 76%-89%. Presence of irritative-
obstructive urinary symptoms and poor sexual drive were associated with approximately 
doubled risk of low global QoL in adjusted analyses.  
 Compared to the other treatment groups, prostatectomized men had more often used 
medication for erectile dysfunction at least once between treatment and survey (84%). In 
addition prostatectomized men initiated such treatment earlier compared to men belonging to 
other treatment groups. Use of medication for erectile dysfunction was not significantly 
associated with global QoL.  
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Table 4: Prevalence of ”typical adverse effect” and low global quality of life (QoL) 
stratified per treatment group* 
 NoTreat RP RADNoHT RADHT
Adverse effects     
Urinary     
   Irritative/obstructive** 50 23 44 35 
   Incontinence 13 24 10 6 
Intestinal     
   Irritative symptoms 21 20 47 42 
   Leakage 3 3 14 14 
Sexual     
   Poor sexual drive 55 61 71 69 
   Poor erectile function 76 89 83 84 
Low global QoL 27 18 30 24 
*Given as percentage of patients with the specified condition in each treatment group 
**Moderate to severe symptoms 
 
 
 
2.5. Discussion 
 
2.5.1 Methodological considerations 
Biases
Bias is a term used for describing any systematic error in a study and can be classified into 
three main categories: selection bias, information bias and confounding [173]. Randomized 
trials reduce most sources of bias, but with the disadvantage that they cannot be generalized to 
all patient groups. In our case men in the RADNoHT group may never have been candidates 
for RP and thus would have been excluded from a randomized trial. In such cases population-
based studies with well-described patients are suitable because they describe the condition in 
the community setting. Our population-based survey is based on information available in the 
CRN when the patients were contacted in 2006. At that time the CRN data for diagnosed PCa 
in 2004 were close to complete regarding the number of patients. The CRN is dynamic and 
data are continuously updated if new information is available. The high quality as to 
proportion of patients being registered can partially be explained by the CRN’s access to 
multiple sources of information such as case record forms, histopathological reports, 
radiotherapy data and death certificates. Due to the high completeness of the CRN as to 
number of cancer cases per year, we consider selection bias in this context to be minimal. 
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  However, 8% of non-metastatic patients could not be categorized into risk-groups 
because of missing data for T-category, PSA and/or Gleason score, which might be a source 
of selection bias.  
 Selection bias might also be present in papers II-IV which rely on self-selection of 
patients to respond to a survey. Unfortunately NorPD data were only released for consenting 
study compliers, which prevented us from doing an attrition analysis. The associations we 
have studied and the prevalences we have described might differ between compliers and non-
compliers to the survey. We can speculate that heavily fatigued men were less likely to 
respond to the survey due to the burden the questionnaire completion may represent. On the 
other hand, men volunteering to complete the questionnaire might be especially bothered by 
symptoms related to PCa and its treatment. In extension to this, men without bothersome 
problems or dysfunction may have considered survey participation as irrelevant.  
The information bias present in the study is most probably non-differential; meaning 
that misclassification of exposure is unrelated to the occurrence or presence of the dependent 
variable. For example, misclassification of patients in categories of adverse effects may only 
reduce the observed association with global QoL, compared to correctly classified data. Some 
known confounding factors are accounted for in multivariate analyses; however, unknown 
confounding factors can be a problem in cross-sectional studies. Confounding by indication is 
a relevant term when discussing biases in the present study. It relates to the fact that those 
who receive a specific treatment generally differ from those who receive another treatment, 
according to the medical indication of the treatments. In the present study we attempted to 
remove this type of bias by adjusting for risk group, co-morbidity and age in adjusted 
analyses. However, the NoTreat group in Paper IV comprises patients who remain untreated 
due to different indications (watchful waiting and active surveillance), which could not 
principally be separated from each other. 
Validity of the study 
The internal validity of a study deals with the degree to which results can be attributed to the 
effect under study, or can be a product of sampling error and alternative explanations. 
Unknown confounding factors can be differently distributed between groups introducing 
systematical bias. When comparing treatment groups we have controlled for available 
confounding factors, such as known co-morbidity and age. Unknown confounding factors and 
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more precise measures of known confounders may have altered our results, in particular the 
unknown severity of pre-treatment co-morbidity influencing treatment decisions. 
 External validity concerns the question if our results can be generalized to other 
populations. Considering the high response rate of our study and the nature of our unselected 
cohort we probably have a high generalizability of our study results to PCa patients which are 
similar in indication for and selection of curative treatment as in our patients from 2004. This 
means that the results can be used to foresee adverse effects in two-year recurrence-free 
patients without any supplementary treatment beyond that provided initially. However, 
several limitations have to be considered.  
 Most importantly any consideration of our results’ external validity requires some 
aspects of selection of patients for RP versus RAD without ADT. Though we have no pre-
treatment data, the higher prevalence of chronic co-morbidity in the RAD patients makes us 
believe that these group’s data, especially concerning CF, are valid only if patients are 
selected for RAD on the same background as anticipated in this study, including more severe 
co-morbidity, which did not allow major surgery.  
 When the patients in the 2004 cohort were treated with RP this was mainly open 
retropubic technique, however two hospitals in Norway used laparoscopic technique already 
in 2004. Laparoscopic RP and robotic assisted laparoscopic RP are performed by less time 
and with less blood loss compared to retropubic RP [174]. In addition the surgeon has a better 
visualization of anatomical structures which in theory could affect outcomes as free surgical 
margins, urinary incontinence and erectile function, however randomized studies showing 
such differences are lacking [175]. No significant differences in survival between the different 
operative techniques have been documented [174]. Further, our data did not separate patients 
based on nerve sparing procedure. However, taking into account the prevalence of self-
reported erectile dysfunction among patients prostatectomized in Norway in 2009 [176] we 
believe our results can be used with caution also with today’s operative techniques. Steinsvik 
et al report that 86% of patients prostatectomized in 2009 suffer from poor erection one year 
after RP [176].  
 The vast majority of definitive radiotherapy patients were treated with external beam 
radiotherapy and the results may differ after the use of brachytherapy.  
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2.5.2 Discussion of main results 
Paper I 
Paper I indicates issues of future improvement as to registration of variables into the NoPCR. 
At least for non-metastatic patients all essential variables (PSA, Gleason score, T category) 
should be collected for adequate risk-group allocation. Missing variables and missing case 
record forms should be chased as soon as possible by the coding staff at the CRN, as a delay 
in registration complicates the task to provide correct information from the time of diagnosis, 
both for the responsible doctor and for the CRN. Improvement in data collection is also 
needed for better separation of active surveillance as a part of curative treatment and watchful 
waiting in a palliative setting. The NoPCR data registration of diagnostics and treatment must 
be under continuous evaluation by dedicated persons who know about the advancing practices 
concerning PCa. The NoPCR should at any time contain all essential variables which are 
needed for evaluating patients according to the current guidelines. For future years the above 
experiences indicate the need for improved registration of essential data and continuous 
control of their completion either by manual or electronic procedures. Registration of ADT in 
the CRN is difficult as these data are complex concerning type of medication, duration, 
amount of ADT and application method. If possible, individualized NorPD data concerning 
cancer treatment should be made available to the CRN, which would be a practical way to 
collect detailed and very important clinical information lacking today.  
 Another issue to discuss is whether RP, definitive radiotherapy or active 
surveillance is the most appropriate treatment considering the different risk-groups. Only 
randomized trials can show the superiority of either treatment, but such trials are lacking. As a 
next to optimal alternative very long-term follow-up of unselected and well characterized 
patient cohorts can be studied, with the possibility to include comparable patients without any 
initial local treatment. This latter aspect is of particular relevance for the low-risk group. 
Improved data collection in the NoPCR will probably enable such comparative survival 
analyses. 
 Further, our population-based registry study revealed patterns of the cancer 
management which might be issues for improvement. Firstly the data indicated over-treatment 
of low-risk PCa, as 57% received definite local therapy within the first 6 months (RP) or 14 
months (definitive radiotherapy). Today’s literature suggests that at least some of these 
patients from the low-risk group can be included in an active surveillance policy, without 
reducing the prognosis, but minimizing the burden of typical adverse effects [177, 178]. This 
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is probably especially valid for patients >65 years for whom the results of RP were equal to 
those of conservative management. A registry study from Sweden reported the 10-year 
cancer-specific mortality for those with low-risk disease to be 2.4% and 0.7% in 
conservatively managed patients and patients treated with curative intent, respectively [179]. 
In the previous Swedish study 60% of patients in the low-risk group were treated with 
curative intention. Local treatment may thus be justified in some men with low-risk tumors, in 
particular in the youngest. The extensive use of local treatment in 2004 is difficult to defend, 
seen with today’s knowledge, especially in men close to their 70ies, for whom survival was 
not prolonged in the SPCG-4 study [177, 178]. Any survival benefit from therapy in low-risk 
patients is bound to be small, however randomized studies are needed. Follow-up studies in 
the NoPCR are needed to prove whether the treatment pattern has changed the most recent 
years. 
 Secondly the data suggest under-treatment of intermediate and high-risk patients 
defined as CurCands as only 68% and 61% received definite curative treatment, respectively. 
At the localized stage PCa is still a potentially curable disease. The probability to undergo 
curative treatment decreased with increasing PSA level in the intermediate- and high-risk 
groups. Recent data indicate that local treatment may be beneficial in these patients, even 
though not always curative [66]. Widmark et al found that patients with high-risk PCa treated 
with definitive radiotherapy and ADT had significantly better PCa specific survival and 
overall survival compared to patients treated with ADT alone [66].  
 Finally, the paper documented that Norwegian urologists and oncologists in general 
followed the recommendations stated in the 2003 EAU guidelines, both in patients who were 
planned for curatively intended treatment, but also for those with metastatic treatment. At the 
same time the paper documented the fact that some hospitals have a small annual number of 
prostatectomies per year and thereby surgeons with low-volume of RP procedures. This issue 
is worth mentioning since an association between high-volume surgeons and better post-
prostatectomy outcomes has been found where low, medium and high volume are defined as 
<18 RPs, 18-52 RPs and >52 RPs a year, respectively [180]. If desirable a cancer registry 
could be used for such surveillance purposes on hospital and/or surgeon level related to 
outcome variables.   
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Paper II and III (chronic fatigue) 
In Norway in 2004 RP was the preferred treatment for the majority of men with low-risk PCa, 
but if co-morbidity and age did not allow this surgical procedure, RAD without adjuvant 
hormone therapy was the most often used curatively intended treatment. Such selection bias 
can also explain why hormone-naïve RAD patients report significantly more CF (26.1%) 
compared to men after RP (13.4%). Interestingly, only 40% of RAD monotherapy patients 
were in the low-risk group and as many as 16% were high-risk patients. Though we only have 
information on post-treatment co-morbidity, the nature of reported conditions suggests that 
many patients suffered from these diseases already at the time of diagnosis and prior to 
treatment decision. Co-morbidity and high age probably had a high impact on the treatment 
decision. However, we cannot exclude that our findings reflect an etiological relationship 
between radiotherapy and CF. High-dose radiotherapy induces long-lasting inflammatory 
processes [181, 182], with chronic overproduction of cytokines and subsequent long-term 
development of fibrosis and necrosis in normal tissue [183], which might be connected to CF. 
In contrast to the patients with (neo)adjuvant ADT, patients with RAD as monotherapy 
probably are less likely to recover from CF with time. Moreover, the comparison of the 
prevalence of post-RP fatigue with that of the normal population may be debatable. RP 
patients are usually selected based on their good health and a life expectancy of more than 10 
years. Pre-treatment CF is probably less of a problem for RP candidates compared to the 
normal population. The prevalence of post-RP CF which is only slightly above that of the 
normal population may thus reflect true increase compared to the pre-treatment level. 
 A cross sectional study from the United Kingdom, similar to Paper II, investigated 
“clinically-relevant fatigue” in recurrence free patients >1 year after RP or radiotherapy [184]. 
Storey et al found the prevalence of “clinically relevant fatigue” to be 33% (95% CI: 27% to 
39%) after radiotherapy and 22% (95% CI: 16% to 30%) after RP. Patients in this study are 
not well characterized at baseline except from age, which in this case was not significantly 
associated with “clinically relevant fatigue”. All radiotherapy patients also had three months 
of neoadjuvant ADT which may have influenced the prevalence of fatigue. However the 
largest difference compared to our study was the high prevalence of “clinically relevant 
fatigue” in the RP group. Only randomized prospective studies can prove whether and to what 
degree radiotherapy can cause CF more than RP.  
 The addition of hormones did not increase the risk of CF in the HTdis group compared 
to hormone-naïve RAD. The two mentioned groups had similar age distribution and 
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proportion with co-morbidity and therefore one might suspect that radiation treatment in itself 
was the most important factor in the development of CF. However, we believe that most of 
our hormone-naïve RAD patients might have been at poorer health at baseline, disqualifying 
them from RP. On the other hand patients receiving RADHT had this combined treatment due 
to more advanced disease and not as a result of more co-morbidity. The relatively high 
estimate of CF in the HTdis group (22.3%) might thus be a result of previous ADT.  
The HTcont group had the highest proportion of CF (39.0%) reflecting a well-known 
negative influence of long lasting hormone treatment on vitality, which has to be balanced 
against inhibition of PCa cells by castration levels of testosterone [185]. ADT for PCa, with 
corresponding low serum testosterone level, has proved to be associated with several adverse 
effects as hot flashes [186], skeletal problems [187, 188], sexual dysfunction [189, 190], 
metabolic changes [191-193] with subsequent increased cardiovascular risk [194], possible 
cognitive impairment [195] and fatigue [156, 157]. Most adverse effects will be reversed with 
subsequent recovery of testosterone production when ADT is discontinued. Normalization of 
testosterone levels appears to be dependent upon ADT duration, baseline testosterone level 
and the age of the patient at initiation of ADT treatment [124]. However, the optimal duration 
of ADT related to the individual patient’s risk-group is uncertain. With treatment duration 
shorter than three years 65% of patients return to their baseline level of testosterone after a 
median follow-up of 18 months [196]. A longer interval to testosterone recovery might 
prolong the duration of adverse effects; however long-term ADT has shown to be associated 
with a lower risk of PCa death in men with minimal co-morbidity [197]. The median time 
during which the HTdis group had been without ADT was 18 months and some would 
therefore not have reached their baseline level of testosterone thus explaining the CF even 
after several months without ADT.      
 Unexpectedly, age was negatively associated with CF in both Paper II and III. As an 
explanation we suggest that CF at a greater extent prevents performance of daily chores and 
leisure activity in younger pre-treatment active men than in older more sedate men. On the 
other hand, the pattern for CF in the normal population is that CF increases with advancing 
age. 
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Paper IV 
The study population in Paper IV differs slightly from patients in Paper II and III, as only 
CurCands were included. The NoTreat group consisted of both true active surveillance 
patients and of men on watchful waiting who were candidates for palliative treatment if the 
disease progressed. Results should not be extrapolated to patients outside our CurCands 
definition or to patients with treatment for PCa recurrence. Separate studies should be 
performed for these patient groups. A rather high number (73 patients) received curatively 
intended therapy, but were by us not defined as CurCands due to old age, poor performance 
status, major co-morbidity or other cancer. This result may reflect that clinicians perform 
individualized evaluations of patients where old age and poor health condition are considered 
unimportant compared to for example the patients’ wishes.  
 The treatment strategies we studied (NoTreat, RP, RADNoHT, RADHT) showed 
distinct patterns of prevalence of typical adverse effects. The investigations were restricted to 
study functional aspects of adverse effects, not taking into account the persons bother. It is 
known that similar degrees of urinary incontinence can be experienced as a great bother or not 
as bothersome depending on the individual [198]. 
 Men in the NoTreat group were not spared from urinary incontinence or irritative-
obstructive urinary symptoms. Irritative-obstructive urinary symptoms in these patients most 
probably originated from malignant and benign growth of the prostate. We can not exclude 
that some men were treated with TUR-P before survey which may have affected our estimates 
concerning urinary function. Low prevalence of irritative-obstructive urinary symptoms 
among men in the RP group may point toward that treatment with RP relieves post-treatment 
irritative-obstructive urinary symptoms, not quite unusual in men above the age of 50 years. 
However, the RP group had a significantly higher prevalence of urinary incontinence 
compared to all other groups. Interestingly, irritative-obstructive urinary symptoms were 
associated with increased risk of low global QoL and should be recognized as a typical 
adverse effect of similar significance as urinary leakage. The significance of irritative-
obstructive urinary symptoms has also been emphasized by Sanda et al [129] and Pardo et al 
[130]. Pardo et al found that irritative-obstructive symptoms were relieved in 64% three years 
after RP, however the prevalence of such symptoms at baseline is not reported. 
 Poor sexual drive and poor erectile function were common in all treatment groups 
though we stress that there might be subgroups performing better for example those operated 
with a nerve-sparing technique [199, 200]. Surprisingly, poor erectile function was not 
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significantly associated with global QoL in our study. However our categorization of patients 
according to use of medication for erectile dysfunction suggests that men have reported sexual 
function without the use of aids, which may have confounded the calculated association 
between erectile function and global QoL. Poor sexual drive was significantly associated with 
low global QoL, probably because it is a more general symptom related to vitality and energy. 
Not surprisingly poor sexual drive was most common among RADNoHT patients (71%) 
supporting our suggestion that this group has a poorer health condition. Poor sexual drive was 
also common among men who had (neo)adjuvant ADT who may still suffer from a low 
testosterone level. Logically men with poor sexual drive were less likely to try medication for 
erectile dysfunction compared to men with normal sexual drive, reflecting their lack of 
motivation to try such treatment.   
  
Neuroticism 
Neuroticism was included as a variable in Paper II-IV and was associated with CF in Paper II 
and III and with global QoL in paper IV, even in adjusted analyses. CF in the general 
population is associated with neuroticism through genetic mechanisms [201] and some PCa 
patients may therefore be predisposed to develop CF under the stress from PCa treatment and 
adverse effects. Evidently this personality trait also plays a role in symptom reporting and 
how a man perceives his health status [167].  
 The public health significance of neuroticism is discussed by Lahey [202] in a 
review article which states that neurotic trait is robustly correlated to many physical and 
mental disorders and a person’s use of public health services. Lahey considers neuroticism to 
be of enormous importance to the public health and suggests intensive research to understand 
relations and mechanisms among neuroticism, mental health, physical health and QoL. 
Previously, Costa &McCrae have stated: «…it (author’s remark: neuroticism) is intimately 
linked to health perceptions and behaviors, and thus to every interaction of the individual with 
the health care system» [167]. The role of this personality trait in clinical and public health 
research has nevertheless not been finally established.  
 Recognition of a nervous personality can be of value during pre-treatment 
counseling having in mind that this condition increases the perception of unavoidable adverse 
effects. Including a measure of neuroticism into pre-treatment counseling can potentially help 
clinicians to provide improved individualized information which render realistic expectations 
as to life after curative treatment for PCa.  
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2.6 Conclusions 
 The initial management of PCa in Norway was largely in accordance with the 2003 
EAU guidelines. There was some evidence of over-treatment of low-risk patients and under-
treatment of intermediate and high-risk patients. If the NoPCR shall be a research tool and 
function as a source of enhancement of medical care of PCa patients in Norway, the routine 
registration of the essential diagnostic variables must be improved and kept at least as 
complete as in 2004. Revision of the case record form is necessary, for example for better 
separation of conservatively managed patients into active surveillance and watchful waiting.  
  Our findings support a possible role of definitive radiotherapy in the development of 
CF in PCa patients, but the observations may be confounded for example by unknown pre-
treatment co-morbidity. As many as 26.1% of hormone-naïve RAD patients had CF 
approximately two years after treatment, which is a substantial proportion and more than one 
would intuitively presume given the total absence of ADT. In addition 30% of men in this 
group had low global QoL. Regardless of the influence of confounding factors this treatment 
group is characterized by distinct health problems and should receive special attention during 
aftercare. Younger age, high neuroticism, co-morbidity, pain and urinary and intestinal 
dysfunction significantly increased the risk of CF implicating that management of CF requires 
pain and symptom relieve.  
 The high prevalence of CF in RADHT patients with ongoing adjuvant ADT is an 
incentive to keep the duration of such treatment as short-lasting as possible without reducing 
the cure rate.  
 Our findings support that different treatment modalities are followed by distinct 
patterns of adverse effects. However, patients who are without treatment also experience 
symptoms viewed as “typical” after curative treatment for PCa. The presence of irritative-
obstructive urinary symptoms and poor sexual drive are associated with increased risk of low 
global QoL. Irritative-obstructive symptoms should thus be recognized as a distinct adverse 
effect in PCa patients. Our results further suggest that the personality trait neuroticism is 
related to global QoL and CF. The use of medication for erectile dysfunction is most common 
after RP treatment, but does not seem to be related to global QoL. To study the effect of 
medication for erectile dysfunction requires that the relevant questionnaire specifically ask for 
sexual function with or without the use of such medication.  
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2.7 Future perspectives 
 The prevalence of typical adverse effects and their impact on global QoL should be 
studied prospectively in a national study, using validated questionnaires and 
comparing the results with similar studies from other cultures. After the initiation of 
this cross-sectional study a prospective national study of adverse effects in Norwegian 
PCa patients treated with curative treatment was initiated 
 As a consequence of the first experiences with the use of the NoPCR data, a new 
version of the PCa specific case record form was developed and put into use for 
patients diagnosed from 2009 and forward.
 
 Few studies are published which describe the typical adverse effects ten years or more 
after curative treatment. Though prospective studies including pre-treatment data are 
important, our well-described cohort of men is in our opinion too valuable to be left 
uninvestigated. We also recommend that survival analyses for 2004 patients are 
performed stratified for treatment modality and risk-group.  
 In extension to the studies we did on CF, adverse effects and global QoL as single 
outcomes after curative treatment for PCa, we recommend that future research projects 
describe the total symptom burden reported by the individual and also identify men 
who are without any burden after their curative treatment for PCa. Such information 
would be more relevant for patient counseling purposes than the information on 
individual single adverse effects.. 
 As a last comment we had an enormous advantage of the access to the NorPD data as 
it was crucial for identification of treatment groups. The NorPD provided information 
on ADT use and on the use of medication for erectile dysfunction. The access to use 
NorPD data was unreasonably difficult and required written informed consent from 
the patients. In the future, access to these data should be made easier, especially those 
related to the outcome of cancer. In our view the level of sensitivity is the same as for 
other treatment already recorded in the CRN as for example orchiectomy, which does 
not require the individual patient’s consent. 
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SUMMARY
OBJECTIVES
 To provide population-based estimates of “typical adverse effects” (AEs) such as 
urinary, bowel and sexual dysfunction in patients with non-metastatic recurrence-free 
prostate cancer (PCa) by curative treatment modality, including observation. 
 To describe associations between typical AEs and global quality of life (QoL), to 
study patients’ use of medication for erectile dysfunction (EDmed) and the relation 
between such use and global QoL 
 
PATIENTS AND METHODS 
 In October 2006 a national population-based sample of PCa survivors diagnosed in 
2004 was invited to a postal survey focusing on treatment-related AEs and global QoL 
12-32 months after treatment start. All had completed their initial treatment. 
 In the present study 771 compliers were categorized into four groups of localized or 
locally advanced PCa related to the treatment they completed: 1) No treatment, 2) 
Radical prostatectomy (RP), 3) Radiotherapy without hormones and 4) Radiotherapy 
with hormone therapy of 3-24 months duration.  
 Measurement of AEs was restricted to function, using selected items from the EPIC-
50 and the Brief Sexual Function Inventory (BSFI) among others, whereas global QoL 
was measured with SF-12. 
 National prescription data enabled assessment of adjuvant hormone application and 
EDmed use.  
RESULTS
 Prostatectomized men reported more urinary incontinence (24%) compared to the 
other treatment groups, but had the lowest level of moderate/severe urinary irritative-
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obstructive symptoms. Men from the “No treatment” group had the highest level of 
moderate/severe irritative-obstructive urinary symptoms. Irradiated men reported 
higher levels of irritative intestinal symptoms and fecal leakage compared to RP and 
the group without treatment. 
 In all treatment groups poor sexual drive and poor erectile function were common 
AEs; with men treated with RP reporting the highest prevalence of poor erectile 
function (89%). 
 Presence of irritative-obstructive urinary symptoms and poor sexual drive were 
independently associated with low global QoL in multivariate analyses.  
 Fifty percent of the study group had ever used EDmed after treatment start, but only 
47% of them were still using EDmed at the time of the survey. Use of EDmed was not 
significantly associated with global QoL. 
CONCLUSION 
 PCa survivors after curative treatment, but also patients without any anti-cancer 
therapy, report high levels of urinary and sexual AEs.
 Irritative-obstructive urinary symptoms and poor sexual drive were significantly 
associated with low global QoL, whereas erectile function and use of EDmed were 
not.
Keywords: curative treatment, adverse effects, global quality of life, neuroticism, medication 
for erectile dysfunction 
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INTRODUCTION
Erectile, urinary and bowel dysfunction are “typical adverse effects” (AEs) after local 
treatment for prostate cancer (PCa) (radical prostatectomy [RP ] and radiotherapy [RAD]) 
though the published estimates vary considerably [1-8]. Missing information about additional 
androgen deprivation therapy (ADT) and relapse make interpretation of these findings 
challenging. The prevalence of AEs depends on treatment modality, baseline characteristics, 
time elapsed since treatment and assessment methodology, which eventually should separate 
function from bother [9]. After RP, most AEs develop immediately after treatment with 
gradual improvement during the first year, whereas AEs after RAD develop more slowly. 
Maximum recovery is usually achieved during the first two post-treatment years [3]. 
Simultaneous use of adjuvant ADT decreases sexual function and leads to increasing fatigue 
[6]. Further, some of the symptoms described as treatment-related AEs may be experienced 
by PCa patients who never had treatment, such as erectile dysfunction (ED) and urinary 
urgency and frequency [10]. In Europe, reports on typical AEs are usually based on mono-
institutional experience or multi-center studies, performed at high volume university-affiliated 
hospitals. Estimates published on AEs include patients with recurrence and additional 
treatment. It is debatable to what extent such studies can serve as basis for counseling 
regarding typical AEs in unselected patients.   
Global quality of life (QoL) describes physical and mental health status as reported by 
the patient, separate from typical AEs. Though AEs are reported as bothersome to patients, 
they are not always associated with reduced global QoL when other factors such as co-
morbidity and age are taken into account [11]. Further, results from cross-cultural studies 
indicate that cultural and national differences influence such associations [12,13]. In 
Norwegian PCa patients for example sexual function was not significantly associated with 
global QoL after radiotherapy [14] contrary to the findings in an American study [4]. More 
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information is therefore needed regarding the relationship between global QoL and typical 
AEs in patients in different cultures preferably derived from population-based studies.  
Lastly, neuroticism is a personality trait which is closely linked to health perception 
[15] and should be accounted for in this context. Of the personality traits presented in the five-
factor model of Costa and McCrae [16], neuroticism has proven to be robustly correlated to 
several mental and physical health outcomes [17]. An individual’s degree of neuroticism 
develops from early childhood and remains relatively stable after young adulthood. Elderly 
men facing the physical and mental health challenges from a PCa diagnosis do so with their 
established degree of neuroticism. In previous studies from our research group neuroticism 
has proven to be a relevant variable when assessing symptoms (e.g. sexual bother) and global 
QoL [18,19]. 
ED is one of the most frequently reported AEs after treatment for PCa. Treatment for 
ED is available such as the use of phosphodiesterase type 5 inhibitors (PDE5 inhibitors). In an 
American study about half of PCa patients treated for localized disease tried/received 
treatment for ED once or more during a five year follow-up period [20]. Differences in the use 
of PDE5 inhibitors may exist between different cultures [21], also related to reimbursement 
possibilities for these expensive drugs. In Norway, medication for ED (EDmed) has to be paid 
by the patients themselves. Use of PDE5 inhibitors have shown to improve functional and 
psychosocial aspects of sexual life and may therefore be important for global QoL [22]. Thus, 
the question is open as to what proportions of PCa patients in a population-based sample use 
these agents and whether EDmed use is related to global QoL. 
With this background our population-based study of non-metastatic PCa patients who 
had completed their planned intervention (No treatment, RP, RAD without ADT or RAD with 
ADT) had two aims:  
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1) To estimate the prevalence of typical AEs and low global QoL in relation to treatment. 
Based on the available literature, we hypothesized following a period of median 23 months 
after local treatment that fewer RAD than RP patients without ADT would experience 
sexual and urinary AEs, but more of them would report bowel AEs. Further, we expected 
adjuvant ADT to increase the prevalence of ED, without significant impact on bowel or 
urinary AEs.  
2) Independently of treatment group, to explore the association between typical AEs and low 
global QoL. In a sub-analysis we investigated the use of EDmed and the relation between 
such use and global QoL.  
 
 
PATIENTS AND METHODS 
Data sources 
Based on the unique personal identification number assigned to each Norwegian citizen data 
were obtained by merging two population-based registries, the Norwegian Prescription 
Database (NorPD) and the Cancer Registry of Norway (CRN) with its radiotherapy and PCa 
registries. Candidates for curative treatment (CurCands) were identified among patients 
diagnosed with PCa in 2004 (T1–3 N0-XM0 category, PSA level 100 ng/mL, any Gleason 
score, age 75 years, ECOG performance status 0–1, no other cancer, no major pre-treatment 
co-morbidity reported on the registration form to the CRN in the optional field for comments 
[23]. 
 
Treatment
Information about RP and RAD was obtained from the CRN. The decision on whether or not 
to apply curative treatment depends upon the patient’s preference and the doctor’s evaluation 
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of the medical situation, with “no curative treatment” being one of the options. The pattern of 
care for men who were to receive curative treatment for PCa in Norway in 2004 is 
summarized as follows based on D’Amico risk groups [23,24]: Low risk: RP or RAD without 
hormones. Intermediate risk: RP or RAD with ADT of variable duration depending on 
patient preference, but not longer than 2 years. High risk: RAD with 2-3 years ADT duration. 
  In October 2006 a national cross-sectional survey of all Norwegian PCa survivors 
diagnosed during 2004 was conducted. Survivors were invited to complete a questionnaire 
concerning global QoL, AEs, lifestyle and psychosocial issues. The present study covers 
responding PCa patients whose eligibility criteria are depicted in Figure 1.  
The following groups were defined based on the patient’s local treatment:   
Group 1: Patients who did not receive any form of anti-cancer treatment (NoTreat). 
For this group the date of diagnosis served as “treatment start”. 
Group 2: RP as monotherapy (RP). Except for the date of RP (“treatment start”) no 
information was available about the operative procedure. 
Group 3: Definitive radiation therapy without any additional treatment (RADNoHT). 
Group 4: Definitive radiation therapy combined with (neo-)adjuvant ADT, the last 
3-month luteinizing hormone-releasing hormone (LHRH) depot injection applied at least 6 
months before the survey (RADHT). 
All irradiated patients received a target dose of 70 Gy to the prostate. “Treatment 
start” was defined as the day of the first session of radiation. 
Measurements
Patient characteristics 
Patients were divided into risk categories using a slightly modified D’Amico risk assessment 
where T2x was categorized as T2a, and all T3 cancers were allocated to the high-risk group 
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[23]. Age was included as a continuous variable. Paired relationship was present if patients 
were married or cohabiting. Higher education was defined as > 12 years of education. Co-
morbidity at the time of the survey implied the report of at least two of 18 co-morbid 
conditions listed in the questionnaire, such as myocardial infarction and diabetes. 
 
AEs 
The survey questionnaire was developed in 2005 and after discussion with experienced 
oncologists and urologists it was decided to use selected items from published questionnaires 
and supplementary study-specific ad hoc questions. For the current study only items 
concerning function were selected and AEs were dichotomized into clinically meaningful 
groups. 
The International Prostate Symptom Score (IPSS) [25] measures irritative-obstructive 
urinary symptoms. The IPSS categories used were; none/mildly symptomatic (0-7), 
moderately symptomatic (8-19) and severely symptomatic (20-35) [26], with further 
dichotomization (0: no symptoms/mildly symptomatic and 1: moderately/severely 
symptomatic). Internal consistency for IPSS was 0.75. 
Urinary incontinence (UI) was defined as “leaking urine at least once a day”, 
categorizing the degree of leakage into “dribbling” versus “more than just dribbling”. 
Irritative intestinal symptoms, measured with selected questions from the EPIC-50 
[27], were defined as experiencing one or more of the following problems; (1) defecation 
three times a day or more; (2) about half the time or more often diarrhea, blood or mucus in 
stool or painful defecation; (3) At least two times a week cramps or fecal urgency.  
Presence of fecal leakage was defined if occurring at least once a week. 
Sexual function was evaluated with the validated instrument Brief Sexual Function 
Inventory (BSFI) [28,29]. Only the drive and erection ratings from BSFI were used, ranging 
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from 0-8 and 0-12, respectively. Higher scores indicated better function. Sexual drive rated as 
3 was defined as “caseness/poor” as was erectile function rated 7 [30]. The questionnaire 
did not specify if sexual function was reported with or without the use of EDmed. Internal 
consistencies for drive and erection were 0.85 and 0.94, respectively.    
Global QoL was measured by the physical and mental component summary scores 
(PCS and MCS) of the SF-12 [31] validated in a Norwegian population [32]. Internal 
consistency was 0.77 for PCS and 0.77 for MCS. The scores of PCS and MCS were T-
transformed with a mean score of 50 for the general population and a standard deviation (SD) 
of 10. Low global QoL was defined as PCS and/or MCS of 40 or below. 
 As symptom-reporting and physical complaints may be influenced by a person’s 
neuroticism, we also measured this personality trait. Neuroticism describes if a person 
generally feels anxious or safe. People with high neuroticism are likely to interpret even 
normal situations as problematic or threatening [15]. An abbreviated version of the Eysenck 
Personality Questionnaire (EPQ-18) measures neuroticism [33,34]. Six items comprise this 
personality trait (range 0-6) which ranges from feeling safe (score 0) to feeling quite nervous 
(score 6). Internal consistency for the EPQ-18 neuroticism was 0.73. Three categories were 
defined; low neuroticism: score 0-1, moderate neuroticism: score 2-3 and high
neuroticism: score 4-6.  
Prescribed EDmed (PDE5 inhibitors, Alprostadil urethral sticks and Papaverin 
injections) were identified using the NorPD database. Patients who had no records of 
prescription of EDmed between treatment and survey were defined as “never users”. Men 
with any EDmed prescription between treatment start and survey were defined as “ever 
users”, independent of the number and amount of prescribed medication. “Ever users” were 
further divided into those who reported use of EDmed during the last four weeks prior to 
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survey (“still users”) and those who did not (“discontinued users”). All but eight men (96 %) 
who stated use of EDmed in the self-report questionnaire were identified in the NorPD data.  
 
STATISTICS 
The dataset was described with mean and SD for continuous, normally distributed variables 
and with median and range for variables with skewed distributions. Categorical variables were 
described with proportions and percentages. Crude associations between pairs of variables 
were assessed using t-tests, Mann-Whitney-Wilcoxon tests, Chi-square tests and One-way 
ANOVA. Adjusted associations between pairs of variables in different treatment groups were 
explored with logistic regression analyses. Internal consistencies of scales were given by 
Cronbach’s coefficient alpha. Factor analyses were not performed. 
Univariate and multivariate associations between typical AEs and low global QoL 
were explored with logistic regression analyses. Due to limitations of statistical power it was 
not possible to include all AEs and significant confounders in one logistic regression model. 
A separate multivariate regression analysis was performed for each AE to investigate its 
association with low global QoL. Each sub-analysis was adjusted for age, education, co-
morbidity and level of neuroticism. The associations between AEs and low global QoL were 
assumed to be similar for all treatment modalities, and therefore all treatment groups were 
combined in the regression analyses (treatment group was not included as a variable).  
All tests were two-sided and the level of significance was set at p<0.01 due to multiple 
testing. The dataset was analyzed using PASW version 18 (IBM, Chicago, IL). 
ETHICS
The study was approved by the Regional Ethics Committee of Southern Norway.  
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RESULTS 
After one reminder 2193 (73%) of 2998 invited patients responded to the national survey. Of 
these, 771 patients were eligible for the present study (Figure 1). At the time of the survey the 
median age of the total sample was 66 years (range 45-75), and a median of 23 months (range 
12-32) had elapsed since start of local treatment. RADHT patients had used ADT for a 
median of six months [range: 3-24 months] and had received their last 3-month LHRH depot 
injection a median of 21 months [range: 7-30 months] before the survey. NoTreat patients 
were significantly older and RP patients were significantly younger than the other treatment 
groups (Table 1). As expected, significantly more men with RADHT belonged to the high risk 
group (61%), compared to the other treatment groups. Of the whole study population 45% 
reported co-morbidity, with significantly lower prevalence in the RP group compared to 
NoTreat and RADNoHT, the latter two groups displaying the highest prevalence of co-
morbidity (53%). Neuroticism was evenly distributed among the treatment groups. 
AEs 
Statistically significantly fewer RP patients reported moderate/severe irritative-obstructive 
urinary symptoms (23%) compared to NoTreat (50%) and RADNoHT (35%) when adjusted 
for age, risk-group and co-morbidity. Among RP patients 24% had UI, significantly higher 
than the other groups (Table 2A, Figure 2A).  
Intestinal symptoms and fecal leakage were most common in irradiated patients; the 
estimates were significantly higher compared to the NoTreat and RP group (Table 2A, Figure 
2B).     
Poor sexual drive was common (>50%) in all treatment groups, with significantly 
lower prevalence (55%) in the NoTreat group. Poor erectile function was also frequently 
reported in all treatment groups (>75%). The highest proportion of poor erectile function was 
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observed among RP patients (89%), which was significantly higher than both the NoTreat 
group and the RADNoHT group (Table 2A, Figure 2C).  
 
Global QoL 
Compared to the other groups RP patients had the lowest proportion of men with PCS40 
(11%), the statistical difference disappeared after adjustment for age, risk-group and co-
morbidity. The proportion of men with MCS 40 was similar in all treatment groups (11% for 
all groups combined). The prevalence of low global QoL was 18% in the RP group (Table 
2B), with the RADNoHT group reaching a statistically significantly higher level (30%).      
 
Associations with global QoL 
All typical AEs (moderate/severe IPSS, UI, irritative intestinal symptoms, fecal leakage, poor 
sexual drive and poor erectile function) were significantly associated with low global QoL in 
univariate analyses (Table 3B). Low educational level, co-morbidity and moderate or high 
neuroticism were all statistically significantly associated with low global QoL in univariate 
analyses (Table 3A). No significant associations with global QoL were observed for age, 
paired relationship and D’Amico risk group. Age was considered an important confounder 
and was therefore adjusted for in the multivariate analyses.  
In the multivariate analyses (Table 3B) the presence of moderate/severe irritative-
obstructive urinary symptoms and poor sexual drive were each statistically significantly 
associated with increased risk of low global QoL. Urinary incontinence, intestinal symptoms, 
fecal leakage and poor erectile function did not reach statistical significance in the adjusted 
analyses. In all six logistic regression analyses, neuroticism was the variable with the highest 
point estimate of association with low global QoL (data not shown). 
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EDmed 
Of 767 evaluable patients 385(50%) had ever used EDmed, but only 24% were “still users”. 
“Never users” of EDmed were significantly older than the “discontinued” and “still user” 
groups and had a higher prevalence of co-morbidity compared to “still users” (Table 4). Poor 
sexual drive was significantly more prevalent among “never users” (71%), compared to “still 
users” (50%). The prevalence of poor erectile function was similar in men from the three 
EDmed groups. Between the three groups of EDmed users no significant differences emerged 
for low global QoL when co-morbidity and age were adjusted for.  
Significantly more men in the RP group were “ever users” of EDmed compared to the 
NoTreat, RADNoHT and RADHT groups (Table 5). Men in the RP group were prescribed 
EDmed closer to treatment start compared to men in the other treatment groups.  
DISCUSSION 
Our population-based study documents that cure from PCa has its price, but that 
“no treatment” is also associated with symptoms similar to “typical AEs”. Two types of 
urinary AEs emerged with different patterns in the treatment groups. While the prevalence of 
UI was highest after RP (24%) irritative-obstructive symptoms were most often recorded by 
irradiated or NoTreat patients (35-50%). Intestinal AEs were more common after RAD 
compared to RP or NoTreat. More than half of the patients in all groups reported poor sexual 
drive, though it was significantly less often reported by NoTreat patients. Poor erectile 
function was reported by more than 75% of men in all treatment groups, most often after RP. 
Despite having typical AEs, the global QoL of men with discontinued curative treatment was 
good for 75%. In adjusted analyses irritative-obstructive urinary symptoms and poor sexual 
drive each approximately doubled the risk of low global QoL, whereas UI, intestinal 
symptoms and poor erectile function were not significantly associated with low global QoL. 
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EDmed was most often used by prostatectomized patients. Such use was not significantly 
associated with global QoL.  
Our results should be interpreted on the background of the treatment policies valid in 
Norway around 2004. Firstly, today’s surveillance strategy was not implemented as a national 
recommendation. We suspect that high age and chronic pre-treatment co-morbidity allocated 
many men to our NoTreat group. Secondly, the RADNoHT group consisted mainly of 
patients with intraprostatic tumors whose co-morbidity probably did not allow a major 
surgical procedure, which would have been the treatment of choice in Norway at that time. 
These policies explain our high rates of post-treatment co-morbidity and high proportion of 
men with PCS40 in the NoTreat and RADNoHT groups. The high proportion of PCS40 
(23%) in the RADHT group, not different from estimates in the NoTreat and RADNoHT 
groups, is likely due to ADT’s negative impact on physical health, persisting for several 
months after discontinuation of ADT.  
The duration of adjuvant ADT is a matter of ongoing debate. As ADT often leads to 
physical and mental AEs, such treatment should be as short-lasting as possible without 
reduction of its beneficial effect on survival. In real-life planned long-lasting hormone 
treatment is often prematurely discontinued in a patient with severe ADT-related AEs, 
possibly explaining the varying duration of adjuvant ADT in our RADHT group. 
This study adds to the growing evidence that irritative-obstructive urinary symptoms 
represent late AEs which impact on a PCa patient’s global QoL. Published studies have 
emphasized the impact of irritative-obstructive urinary symptoms on satisfaction with 
treatment outcome and global QoL [6,8]. In our study men in the NoTreat and RADNoHT 
groups were more likely to experience these AEs compared to prostatectomized men. Similar 
results were found in the prospective study by Pardo and colleagues where irritative-
obstructive symptoms were reduced in about half of the patients three years after RP [8]. The 
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prevalence of moderate/severe irritative-obstructive urinary symptoms was highest in our 
NoTreat group, probably related to the growth of the prostate gland, though not significantly 
different from the RADNoHT group. 
UI has been the main focus of many studies and, as expected, it was most common 
after RP, but only 10% of our prostatectomized patients described their UI as “more than just 
dribbling”. Prevalence of UI found in the Prostate Cancer Outcomes Study [4] after 24 
months of follow-up was 4.7%, 3.3% and 21.5% for watchful waiting, RAD and RP 
respectively. Steineck et al [10] found that 18% of men randomized to RP and 2% of men 
randomized to watchful waiting reported a moderate to severe degree of urinary leakage after 
a mean follow-up of four years. Our high prevalence of UI in the NoTreat group (13%) and 
severe leakage (8%) must be viewed on the basis of this group’s heterogeneity.
In addition to irritative-obstructive urinary symptoms, poor sexual drive was 
significantly associated with a doubled risk of having low global QoL. Interestingly, and 
contrary to Penson et al’s study [4], the association between poor erectile function and low 
QoL did not reach our level of significance. This may be related to cultural differences in 
patients’ view concerning sexual functioning with increasing age. Response shift must also be 
considered as a possible explanation [35,36]. Response shift reflects the gradual acceptance of 
treatment-related AEs and change of expectations as to global QoL. Based on our results we 
speculate that response shift related to low global QoL develops less easily with regard to 
irritative-obstructive urinary symptoms and poor sexual drive. This is probably because these 
AEs are more disturbing and interfere with the general perception of health.  
Age, education, co-morbidity and neuroticism were identified as confounding factors 
which moderated the observed association between AEs and low global QoL. Even though 
the confounding effect of neuroticism was moderate, level of neuroticism consequently had 
the strongest association with low global QoL (data not shown) which gives further strength 
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to its importance in QoL research. A person’s presence of a moderate or high level of 
neuroticism was more important for reporting low global QoL than erectile or intestinal 
dysfunction or UI. This result also implies that personality should be taken into account when 
informing patients about functional AEs, as nervous men might experience more symptoms 
concurrent with a low QoL, than less neurotic ones.   
Even though treatment for ED is available only about half of our patients had used 
such medication after PCa treatment, most men in the RP group (84%) and fewest in the 
NoTreat group (19%). We cannot decide whether these differences primarily are due to 
varying patients’ demands or if they reflect prescription patterns differing between urologists 
and oncologists. Both explanations are most probably relevant. With today’s knowledge of 
the importance of early activation of nervous pathways responsible for erectile function [37] 
early and more frequent post-treatment management of ED is challenging, also after RAD. 
About half of “ever-users” report that they had not used EDmed within four weeks prior to the 
survey which may indicate that today’s EDmed is not effective for many of these patients. Of 
special interest, and admittedly based on small figures, is the fact that almost two thirds of 
patients from the RADNoHT group were “still users” as compared to less than half in the 
other groups. This may indicate that these drugs are particularly effective after RAD as 
monotherapy. While erectile function was similar in “ever-users” and “never-users”, poor 
sexual drive was significantly more prevalent in the latter group, probably reflecting their lack 
of motivation to try EDmed. Low global QoL was not significantly associated with EDmed 
use and the small proportion of “still users” with low QoL is explained by their younger age 
and fewer co-morbid conditions. 
Several limitations concerning our cross-sectional study should be mentioned, such as 
the lack of pre-treatment data. Not recognized inter-group variability in pre-treatment 
dysfunctions and low global QoL could have introduced a systematic bias. Our choice to 
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select single domains from different instruments for the survey questionnaire instead of one 
complete validated questionnaire is today questionable. Our solution has to be viewed as a 
compromise between interests of oncologists and urologists for whom self-report of AEs was 
a new methodology in 2004. Further, there is uncertainty to whether or not the questions 
about ED have been answered disregarding the use of EDmed. Since 85% of “still users” 
report poor erectile function similarly to “never users” and “discontinued users”, the majority 
has probably reported their function in absence of sexual aids. We propose that future 
questionnaires should clearly separate the patient’s report on erectile function related to the 
use of EDmed.  
The major strengths of our study are the population-based design and the comparison 
of three of today’s major treatment modalities in addition to a “no treatment” group. Further, 
the described typical AEs are those emerging after completion of planned initial treatment 
alone, without the use of adjuvant or salvage treatment. Finally, the reported prevalences of 
typical AEs and low global QoL are probably persistent ones, as several studies have shown 
that PCa related QoL stabilizes 6-12 months post treatment [4,38,39].  
In conclusion, PCa survivors after curative treatment, but also patients without any 
therapy, report considerable rates of sexual, urinary and intestinal AEs. Irritative-obstructive 
urinary symptoms and poor sexual drive each approximately double the risk of low global 
QoL. Use of EDmed was most common among men in the RP group, and was not associated 
with global QoL.  
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FIGURES AND TABLES: 
Figure 1: Attrition analysis leading from all 2193 complying patients to the 771 eligible 
Candidates for Curative treatment (yellow fields). The gray fields cover patients who are 
ineligible due to medical or therapeutic reasons, whereas the red fields reflect study-
related eligibility criteria. 
 
COMPLIERS 
N=2193 
CANDIDATES FOR CURATIVE 
TREATMENT 
N=1287 
TOTAL SAMPLE 
N=771
RAD with 
discontinued ADT 
N=142 
No treatment 
N=180 
RP 
N=293 
RAD 
hormone-naive
N=156 
Not candidates for curative 
treatment 
N=906 
Other treatment category 
N=454 
RP+ADT: n=3 
RAD+ongoing ADT: n=93 
RAD+ other ADT: n=154 
RP +RAD: n=29 
Cryotherapy: n=29 
ADT only: 146  
NoTreat 
n=193 
RP 
n=315 
RADNoHT 
n=174 
RADHT 
n=151 
No treatment 
n=193 
RP 
n=312 
RAD  
hormone-naive 
n=168 
RAD with 
discontinued 
ADT, n=150 
Completion of the Short-Form Health Survey-12 (SF-12) 
Start of eventual local treatment minimum 12 months prior to the survey 
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Figure 2: Percentage of typical side effects per treatment group; A) Moderate/severe 
irritative-obstructive urinary symptoms and urinary incontinence. B) Intestinal 
symptoms and fecal leakage. C) Poor sexual drive and poor erectile function 
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Table 1: Descriptives: Demographics and diagnostics (A) and physical and psychosocial 
condition at survey (B) 
 
A) Demographics 
and diagnostics 
Group 1 
NoTreat 
N=180 
Group 2 
RP 
N=293 
Group 3 
RADNoHT 
N=156 
Group 4 
RADHT 
N=142 
Total 
 
N=771 
Age at survey, median 
[range]* 
70[50-75]2,3,4 62[45-73]1,3,4 67[49-75]1,2 66[48-75]1,2 66 [45-75]
Paired relation, N (%) 
Yes 
No 
 
153 (87) 
23 (13) 
 
266 (92) 
22 (8) 
 
136 (90) 
16 (11) 
 
130 (94) 
9 (7) 
 
685 (91) 
70 (9) 
Higher education 
Yes 
No 
 
58 (34) 
115 (67) 
 
127 (44) 
160 (56) 
 
65 (43) 
85 (57) 
 
55 (41) 
79 (59) 
 
305 (41) 
439 (59) 
Risk group, N (%)* 
Low risk 
Intermediate risk 
High risk 
 
92 (51)2,3,4 
46 (26) 
41 (23) 
 
157 (54)1,4 
100 (34) 
36 (12) 
 
64 (41)1,4 
67 (43) 
25 (16) 
 
15 (11)1,2,3 
40 (28) 
87 (61) 
 
328 (43) 
253 (33) 
189 (25) 
 
B) Physical and 
psychosocial
condition at survey 
     
Co-morbidity, N (%)* 
No 
Yes 
 
84 (47)2 
96 (53) 
 
186 (64)1,3 
107 (37) 
 
74 (47)2 
82 (53) 
 
78 (55) 
64 (45) 
 
422 (55) 
349 (45) 
Neuroticism, N (%) 
Low 
Moderate 
High 
 
105 (61) 
46 (27) 
20 (12) 
 
178 (63) 
71 (25) 
35 (12) 
 
80 (54) 
42 (28) 
27 (18) 
 
74 (54) 
48 (35) 
16 (12) 
 
437 (59) 
207 (28) 
98 (13) 
*At least one significant difference at p<0.01.  
1, 2, 3, 4: indication of groups whose results differ significantly from the actual group 
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Table 2: Prevalence of adverse effects (A) and Global Quality of Life outcomes (B) 
stratified per treatment group 
 
*At least one significant difference at p<0.01 when adjusted for age, risk-group and co-
morbidity. 
1, 2, 3, 4: indication of groups whose results differ significantly from the actual group 
A) Adverse effects 
 
Urinary
Group 1 
NoTreat 
N=180 
Group 2 
RP 
N=293 
Group 3 
RADNoHT
N=156 
Group 4 
RADHT 
N=142 
Total 
N=771 
Irritative-obstructive, N (%)* 
None/Mild sympt. 
Moderate/severe sympt. 
 
88 (50)2,4 
87 (50) 
 
225 (77)1,3 
67 (23) 
 
87 (56)2 
68 (44) 
 
93 (66)1 
49 (35) 
 
493 (65) 
271 (36) 
Incontinence, N (%)*     
No                                      
Yes 
 
157 (87)2 
23 (13) 
 
223 (76)1,3,4
70 (24) 
 
140 (90)2 
16 (10) 
 
134 (94)2 
8 (6) 
 
654 (85) 
117 (15) 
 
Drops 
More than drops 
 
9 (5) 
14 (8) 
 
40 (14) 
30 (10) 
 
13 (8) 
3 (2) 
 
2 (1) 
6 (4) 
 
 
64 (8)    
53 (7) 
 
Intestinal      
Irritative symptoms, N (%)* 
No 
Yes 
 
 
140 (79)3,4 
38 (21) 
 
233 (80)3,4 
59 (20) 
 
83 (53)1,2 
73 (47) 
 
82 (58)1,2 
60 (42) 
 
538 (70) 
230 (30) 
Fecal leakage, N (%)*   
No 
Yes 
Sexual
 
172 (97)3,4 
5 (3) 
 
283 (97)3,4 
8 (3) 
 
133 (86)1,2 
21 (14) 
 
120 (86)1,2 
19 (14) 
 
708 (93) 
53 (7) 
 
Sexual drive (N=763)* 
Normal sexual drive, N (%) 
Poor sexual drive 
 
78 (45)2,3,4 
97 (55) 
 
113 (39)1 
180 (61) 
 
45 (29)1 
109 (71) 
 
44 (31)1 
97 (69) 
 
280 (36) 
483 (63) 
 
Erectile function (N=753)* 
Normal erectile funct. N (%) 
Poor erectile function 
 
 
41 (24)2,3 
131 (76) 
 
 
33 (11)1,3 
258 (89) 
 
 
25 (17)1,2 
126 (83) 
 
 
23 (17) 
116 (84) 
 
 
122 (16) 
631 (84) 
(B) Global QoL outcomes 
     
PCS  40, N (%) 37 (21) 32 (11) 33 (21) 32 (23) 134 (17) 
MCS  40, N (%) 19 (11) 33 (11) 22 (14) 8 (6) 82 (11) 
Low global QoL, N (%)* 49 (27) 54 (18) 3 47 (30)2  34 (24) 184 (24) 
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Table 3: Univariate associations between possible confounders and low global QoL (A) 
and univariate and multivariate logistic regression analyses for each AE, with low global 
QoL as dependent variable (B). 
A) Univariate 
 
OR (95% CI OR)       p-value 
Age (continuous) 1.02 (0.99-1.05) .196 
Paired relation (yes=ref) 1.88 (1.12-3.17) .017 
Education (high=ref) 1.66 (1.16-2.36) .006 
Risk group (D’Amico) (low risk=ref) 
          Intermediate risk 
          High risk 
 
0.97 (0.65-1.44) 
1.57 (1.05-2.36) 
 
.860 
.028 
Co morbidity (no=ref) 3.02 (2.14-4.28) <0.001 
Neuroticism (low=ref)* 
          Moderate 
          High 
 
3.47 (2.27-5.29) 
15.26 (9.14-25.47) 
 
<0.001 
<0.001 
 
B) Univariate 
 
 OR (95% CI OR)     p-value 
Adjusted* 
 
OR (95% CI OR)     p-value 
Moderate/severe irritative-obstructive 
urinary symptoms (no/mild = ref) 
 
3.02 (2.14-4.26) 
 
<0.001 
 
2.34 (1.57-3.50) 
 
<0.001 
Urinary incontinence (no=ref) 2.32 (1.53-3.51) <0.001 1.80 (1.10-2.93) .019 
Intestinal symptoms (no=ref) 2.23 (1.58-3.14 ) <0.001 1.59 (1.05-2.40) .029 
Fecal leakage (no=ref) 2.93 (1.66-5.18) <0.001 2.37 (1.19-4.70) .014 
Poor sexual drive (normal=ref) 2.60 (1.76-3.84) <0.001 2.03 (1.29-3.20) .002 
Poor erectile function (normal=ref) 3.02 (1.65-5.51) <0.001 1.96 (0.99-3.86) .053 
*Adjusted for age, education, co-morbidity and level of neuroticism
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Table 4: Comparison of men not using medication for erectile dysfunction (EDmed) with 
those who had used, but discontinued EDmed between start of local treatment and survey** 
and those still using EDmed at survey 
 “Everusers”N=385
 
1:”Neverusers”


N=382
2:EDmed,“discontinued
users”
N=201
3:EDmed“still
users”
N=184
Age, median [range]* 68 [50-75] 2,3 63 [45-75] 1 63 [48-75] 1 
Co-morbidity, N (%)* 197 (52)3 87 (43) 64 (35)1 
Poor sexual drive*‡ 266 (71)3 124 (62) 92 (50)1 
Poor erectile function‡ 306 (83) 167 (84) 155 (85) 
Low QoL, N (%) ‡ 102 (27) 51 (25) 31 (17) 
*At least one significant difference at p<0.01.  
1, 2, 3: indication of groups whose results differ significantly from the actual group. 
** The NoTreatment group is calculated from the time of diagnosis as a substitute for start of 
local treatment 
‡adjusted for age and co-morbidity 
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Table 5: Post-treatment use of Medication for Erectile Dysfunction (EDmed) in 771 
evaluable men** 
 
 Group1
NoTreat
N=180
Group2
RP
N=293
Group3
RADNoHT
N=156
Group4
RADHT
N=142

Total

N=771
Ever users, N (%)* 35 (19)2,3,4  246 (84)1,3,4 57 (37)1,2 51 (36)1,2 389 (51)
Discontinued users*†, N (%) 19 (54) 129 (53) 20 (35)4 33 (66)3 201 (52)
Still users†, N (%) 14 (40) 116 (48) 37 (65) 17(34) 184 (47)
Months to first prescription after 
treatment start, median [range] 
 
6 [0-29]2 
 
2 [0-19]1,3,4 
 
7 [0-19]2 
 
9 [0-24]2 
 
3 [0-29] 
*At least one significant difference at p<0.01, adjusted for age and co-morbidity.  
1, 2, 3, 4: indication of groups whose results differ significantly from the actual group 
** Calculated from date of start of local treatment (Group 2-4) or date of diagnosis (Group 1)  
†Proportion of ever users. Percentages do not summarize to 100 because of missing 
categorization of patients.  
 
 
 
Appendix A:
Case record form for prostate cancer. This form was in use at the Cancer Registry of 
Norway for patients diagnosed from January 2004 to October 2008.  

MELDING  TIL  KREFTREGISTERET
MONTEBELLO, 0310 OSLO
Veiledning  på  baksiden CANCER   PROSTATAE
Tilleggsmelding  til  ordinært  meldeskjema
PASIENT
Fødselsnr. Postnr. Poststed
Etternavn Fornavn
TILLEGGSOPPLYSNINGER
Meldt:
Pasientansvarlig lege (Etternavn, fornavn - trykte bokstaver)
Id. nummer
Legens underskrift
Id. nummer
INSTITUSJON (sykehus/ avdeling/ legepraksis)
Dag Mnd År
Skjema  i  kraft  fra  01.01.2004
Evt. klistremerke
ÅRSAK  TIL  UTREDNING
1. PSA
      initiert av
lege
pasient
ukjent
2. Palpasjonsfunn
 (rektal eksplorasjon)
3. Urinveissymptomer
4. Metastasemistanke
5. Tilfeldig funn v/ TUR-P
6. Andre årsaker
DATO   FOR   HENVISNING   TIL   SPESIALISTHELSETJENESTEN
Gleason score .......... + .......... =
biopsi
TUR- P
metastase
andre
Morfologisk
basis
spesifiser .................................................
DIAGNOSEGRUNNLAG
PSA ved diagnosetidspunktet
,
μg/l
Ultralyd prostata
utført
ikke utført
Skjelettscintigrafi
positivt funn
negativt funn
ikke utført
Annen
bildediagnostikk
utført
ikke utført
hvilken ..................................................
Lymfadenektomi p N Operasjonsbeskrivelse må vedlegges
FUNKSJONSTILSTAND
0: Normal aktivitet, uten begrensning
1: Lett redusert arbeidskapasitet
2: > 50% av dagen oppegående. Ikke i arbeid, helt selvhjulpen
3: > 50% av dagen i seng/stillesittende. Behov for endel hjelp til personlig stell
4: Helt avhengig av andre. Totalt stillesittende eller i seng hele dagen
PLANLAGTE  TILTAK
Pasienten observeres årsak
alder
dårlig almenntilstand
pasienten ønsker ikke
behandling
ikke medisinsk indikasjon
andre
spesifiser ......................................................
Pasienten får
behandling/ behandling planlagt
(meldes på ordinært meldeskjema)
STUDIEINKLUSJON
Er pasienten inkludert i studie
Ja Nei
hvilken ...................................................................................................................................................
Ikke henvist
spesifiser ............................................................
............................................................................
VEILEDNING TIL UTFYLLING AV SKJEMAET 
MERK AT DETTE ER ET TILLEGGSSKJEMA TIL ORDINÆRT MELDESKJEMA TIL 
KREFTREGISTERET. BEGGE SKJEMAER MÅ FYLLES UT. 
 
Årsak til utredning: Under dette punktet oppgir man de viktigste årsakene til at pasienten ble utredet med hensyn på 
prostatacancer. Det kan krysses av på flere punkter hvis dette er nødvendig.  
 
Gleason score: Primær Gleason grad (1-5) + sekundær Gleason grad (1-5) = Gleason score (2-10) anføres. Eks. Gleason 
grad 3 + grad 4 = Gleason score 7. Er det kun angitt en Gleason grad blir primær og sekundær grad identiske. Eks. 
Gleason grad 3 + grad 3 = Gleason score 6. 
 
Diagnosegrunnlag: De diagnostiske prosedyrer som danner grunnlaget for diagnosen prostatacancer. Usikkert funn etter 
skjelettscintigrafi skal oppgis som negativt funn og eventuelt kommenteres i feltet ”tilleggsopplysninger” nederst på 
meldeskjemaet. 
 
Planlagte tiltak: Utført og planlagt primærbehandling rapporteres også på ordinært meldeskjema.  
 
Definisjon av klinisk TNM for primærtumor i prostata (2002-versjonen). Skal registreres på ordinært 
meldeskjema. Klassifikasjonen gjelder bare adenokarsinom.  
Sykdomsutbredelse bestemmes på grunnlag av følgende diagnostiske/eksplorative prosedyrer: 
T Klinisk undersøkelse, bildediagnostikk, endoskopi, biopsi og biokjemiske undersøkelser. 
N Klinisk undersøkelse og bildediagnostikk. 
M Klinisk undersøkelse, bildediagnostikk, skjelettundersøkelser og biokjemiske undersøkelser. 
 
Definisjon av T-, N- og M-kategoriene 
 
T                        Primær tumor 
TX Primærtumor kan ikke vurderes. 
T0 Primærtumor ikke påvist. 
T1 Klinisk ikke erkjennbar tumor, ikke palpabel eller påvisbar ved bildediagnostikk. 
            T1a   Tumor, tilfeldig funn i 5% eller mindre av resesert vev. 
            T1b Tumor, tilfeldig funn i mer enn 5% av resesert vev. 
            T1c Tumor påvist ved nålebiopsi (f.eks. på grunn av forhøyet PSA). 
T2 Tumor begrenset til prostata. 
NB: Tumor som er påvist i én eller begge lapper ved nålebiopsi, men som ikke er palpabel eller 
påvisbar ved bildediagnostikk klassifiseres som T1c. 
            T2a Tumor omfatter en halv lapp eller mindre. 
            T2b Tumor omfatter mer enn halvparten av en lapp, men ikke begge lapper. 
            T2c Tumor omfatter begge lapper. 
T3 Tumor vokser gjennom prostatakapselen. 
NB: Innvekst i apex prostatae eller inn i (men ikke gjennom) prostatakapselen klassifiseres som T2. 
            T3a Ekstrakapsulær vekst (unilateral eller bilateral). 
            T3b Tumor vokser inn i sædblære(r). 
T4 Tumor er fiksert eller vokser inn i nabostruktur(er) annet enn sædblære(r): blærehals, musculus  
sphincter externus, rectum, levator-muskulatur og/eller er fiksert til bekkenveggen. 
  
N  Regionale lymfeknuter: Lymfeknuter i det lille bekken (mellom bifurkaturen av arteria iliaca       
communis og lyskebåndet). Lateralitet påvirker ikke N-klassifikasjonen 
NX Spredning til regionale lymfeknuter kan ikke vurderes. 
N0 Ingen regionale lymfeknutemetastaser. 
N1 Regional(e) lymfeknutemetastase(r). 
 
M                        Fjernmetastaser (fjerne lymfeknutemetastaser og organmetastaser)  
MX Fjernmetastasering kan ikke vurderes. 
M0 Ingen fjernmetastaser 
M1 Fjernmetastase(r). 
            M1a Metastase(r) til fjern(e) lymfeknute(r). 
            M1b Metastase(r) til skjelett. 
            M1c Annen/andre fjernmetastase(r), med eller uten skjelettmetastaser. 
 
Veiledningen er à jour pr. 01.01.2004. Se eventuelle oppdateringer på Kreftregisterets hjemmeside: 
www.kreftregisteret.no. Kreftmeldingen er hjemlet i Kreftregisterforskriften, i kraft fra 01.01.2002. 
 
Appendix B:
National population-based survey in Norwegian 
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Erratum
Paper 3: The correct institution for affiliation number 4 is the following: National Resource 
Center for Late Effects, Department of Oncology, Oslo University Hospital and University of 
Oslo, Norway.

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